Publications

Selection of CCC-N Publications

2023

• Conche C, Finkelmeier F, Pesic M, Nicolas AM, Bottger TW, Kennel KB, Denk D, Ceteci F, Mohs K, . . . Greten FR. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. Sep 2023;72(9):1774-1782. doi.org/10.1136/gutjnl-2022-327909
• Fokas E, Glynne-Jones R, Fleischmann M, Piso P, Tselis N, Ghadimi M, Hofheinz RD, Rodel C. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat Rev. Jan 2023;112:102490. doi.org/10.1016/j.ctrv.2022.102490
• Hamdan FH, Abdelrahman AM, Kutschat AP, Wang X, Ekstrom TL, Jalan-Sakrikar N, Wegner Wippel C, Taheri N, Tamon L, . . . Johnsen SA. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Gut. Jun 2023;72(6):1174-1185. doi.org/10.1136/gutjnl-2022-328154
• Keck MK, Sill M, Wittmann A, Joshi P, Stichel D, Beck P, Okonechnikow K, Sievers P, Wefers AK, . . . Jones DTW. Correction to: Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. Acta Neuropathol. Apr 2023;145(4):511-514. doi.org/10.1007/s00401-023-02538-4
• Kneist W, Ghadimi M, Runkel N, Moesta T, Coerper S, Benecke C, Kauff DW, Gretschel S, Gockel I, . . . Group NS. Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer: Results From a Multicenter, Randomized, Controlled Clinical Trial of a NEUROmonitoring System (NEUROS). Ann Surg. Apr 1 2023;277(4):e737-e744. doi.org/10.1097/SLA.0000000000005676
• Mansmann U, Locher C, Prasser F, Weissgerber T, Sax U, Posch M, Decullier E, Cristea IA, Debray TPA, . . . Naudet F. Implementing clinical trial data sharing requires training a new generation of biomedical researchers. Nat Med. Feb 2023;29(2):298-301. doi.org/10.1038/s41591-022-02080-y
• Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, . . . Harter P. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. Feb 1 2023;41(4):893-902. doi.org/10.1200/JCO.22.01010
• Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, Ghadimi M, Gallmeier E, Bartsch DK, . . . Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. Jan 2023;34(1):91-100. doi.org/10.1016/j.annonc.2022.09.161
• Sommerhauser G, Kurreck A, Beck A, Fehrenbach U, Karthaus M, Fruehauf S, Graeven U, Mueller L, Koenig AO, . . . Modest DP. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212). Eur J Cancer. Jan 2023;178:37-48. doi.org/10.1016/j.ejca.2022.09.011
• Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, Sievers P, Wefers AK, Ebrahimi A, . . . Jones DTW. Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology. Nat Med. Apr 2023;29(4):917-926. doi.org/10.1038/s41591-023-02255-1

2022

• Adeberg S, Knoll M, Koelsche C, Bernhardt D, Schrimpf D, Sahm F, Konig L, Harrabi SB, Horner-Rieber J, . . . Abdollahi A. DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. Acta Neuropathol. Jul 2022;144(1):129-142. doi.org/10.1007/s00401-022-02443-2
• Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, Diez Campelo M, Gallego MS, Granada Font I, . . . Xu X. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. Apr 14 2022;139(15):2273-2284. doi.org/10.1182/blood.2021014309
• Al-Bourini O, Seif Amir Hosseini A, Giganti F, Balz J, Heitz LG, Voit D, Lotz J, Trojan L, Frahm J, . . . Uhlig J. T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment. Invest Radiol. Jun 1 2023;58(6):380-387. doi.org/10.1097/RLI.0000000000000945
• Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, . . . Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. Jul 2022;36(7):1720-1748. doi.org/10.1038/s41375-022-01620-2
• Albert MH, Sirait T, Eikema DJ, Bakunina K, Wehr C, Suarez F, Fox ML, Mahlaoui N, Gennery AR, . . . Vinh DC. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. Oct 6 2022;140(14):1635-1649. doi.org/10.1182/blood.2022015506
• Albert MH, Slatter MA, Gennery AR, Gungor T, Bakunina K, Markovitch B, Hazelaar S, Sirait T, Courteille V, . . . Lankester AC. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood. Mar 31 2022;139(13):2066-2079. doi.org/10.1182/blood.2021014687
• Alejo-Valle O, Weigert K, Bhayadia R, Ng M, Issa H, Beyer C, Emmrich S, Schuschel K, Ihling C, . . . Klusmann JH. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood. Feb 3 2022;139(5):651-665. doi.org/10.1182/blood.2021012231
• Alsina-Sanchis E, Mulfarth R, Moll I, Bohn S, Wiedmann L, Jordana-Urriza L, Ziegelbauer T, Zimmer E, Taylor J, . . . Rodriguez-Vita J. Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages. Cancer Res. Dec 2 2022;82(23):4414-4428. doi.org/10.1158/0008-5472.CAN-22-0076
• Averbuch D, De Greef J, Dureault A, Wendel L, Tridello G, Lebeaux D, Mikulska M, Gil L, Knelange N, . . . European Study Group for Nocardia in Hematopoietic Cell T. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Clin Infect Dis. Aug 24 2022;75(1):88-97. doi.org/10.1093/cid/ciab866
• Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, . . . Brca. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J Natl Cancer Inst. Jan 11 2022;114(1):109-122. doi.org/10.1093/jnci/djab147
• Bastian L, Hartmann AM, Beder T, Hanzelmann S, Kassens J, Bultmann M, Hoeppner MP, Franzenburg S, Wittig M, . . . Baldus CD. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Leukemia. Jun 2022;36(6):1676-1680. doi.org/10.1038/s41375-022-01557-6
• Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, Yakoub-Agha I, Grassi A, Reinhardt HC, . . . Mohty M. 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Clin Cancer Res. Mar 1 2022;28(5):1004-1012. doi.org/10.1158/1078-0432.CCR-21-2675
• Beelen DW, Stelljes M, Remenyi P, Wagner-Drouet EM, Dreger P, Bethge W, Ciceri F, Stolzel F, Junghanss C, . . . Markiewicz M. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial. Am J Hematol. Aug 2022;97(8):1023-1034. doi.org/10.1002/ajh.26620
• Ben Guebila M, Weighill D, Lopes-Ramos CM, Burkholz R, Pop RT, Palepu K, Shapoval M, Fagny M, Schlauch D, . . . Quackenbush J. An online notebook resource for reproducible inference, analysis and publication of gene regulatory networks. Nat Methods. May 2022;19(5):511-513. doi.org/10.1038/s41592-022-01479-2
• Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, . . . Dreger P. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood. Jul 28 2022;140(4):349-358. doi.org/10.1182/blood.2021015209
• Bielack SS, Blattmann C, Borkhardt A, Csoka M, Hassenpflug W, Kabickova E, Kager L, Kessler T, Kratz C, . . . Hecker-Nolting S. Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). Eur J Cancer. Nov 2022;176:50-57. doi.org/10.1016/j.ejca.2022.09.007
• Bohnsack KE, Kanwal N, Bohnsack MT. Prp43/DHX15 exemplify RNA helicase multifunctionality in the gene expression network. Nucleic Acids Res. Sep 9 2022;50(16):9012-9022. doi.org/10.1093/nar/gkac687
• Breast Cancer Association C, Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, Dennis J, . . . Easton DF. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol. Mar 1 2022;8(3):e216744. doi.org/10.1001/jamaoncol.2021.6744
• Bruni E, Cimino MM, Donadon M, Carriero R, Terzoli S, Piazza R, Ravens S, Prinz I, Cazzetta V, . . . Mavilio D. Intrahepatic CD69(+)Vdelta1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J Immunother Cancer. Jul 2022;10(7) doi.org/10.1136/jitc-2022-004579
• Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde M, Borkhardt A, Burmeister T, . . . Lenz G. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age. Nat Commun. Jul 6 2022;13(1):3881. doi.org/10.1038/s41467-022-31355-8
• Byun J, Han Y, Li Y, Xia J, Long E, Choi J, Xiao X, Zhu M, Zhou W, . . . Amos CI. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet. Aug 2022;54(8):1167-1177. doi.org/10.1038/s41588-022-01115-x
• Ceppi F, Gotti G, Moricke A, Silvestri D, Poyer F, Lentes J, Bergmann A, Trka J, Alten J, . . . Schrappe M. Near-tetraploid T-cell acute lymphoblastic leukaemia in childhood: Results of the AIEOP-BFM ALL studies. Eur J Cancer. Nov 2022;175:120-124. doi.org/10.1016/j.ejca.2022.08.013
• Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, Meylan S, Mehra V, Styczynski J, . . . Pagano L. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. Jun 2022;36(6):1467-1480. doi.org/10.1038/s41375-022-01578-1
• Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, . . . Delord JP. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. Jun 2 2022;41(1):189. doi.org/10.1186/s13046-022-02383-5
• Chauvistre H, Shannan B, Daignault-Mill SM, Ju RJ, Picard D, Egetemaier S, Varaljai R, Gibhardt CS, Sechi A, . . . Roesch A. Persister state-directed transitioning and vulnerability in melanoma. Nat Commun. Jun 1 2022;13(1):3055. doi.org/10.1038/s41467-022-30641-9
• Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H, Mahadevan KK, Wu CJ, Sugimoto H, . . . Kalluri R. Oncogenic collagen I homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. Aug 8 2022;40(8):818-834 e9. doi.org/10.1016/j.ccell.2022.06.011
• Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, . . . Investigators K-. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. Jul 21 2022;387(3):217-226. doi.org/10.1056/NEJMoa2202809
• D'Alessio A, Fulgenzi CAM, Nishida N, Schonlein M, von Felden J, Schulze K, Wege H, Gaillard VE, Saeed A, . . . Pinato DJ. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. Oct 2022;76(4):1000-1012. doi.org/10.1002/hep.32468
• de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, Loukissas JK, Zavadil J, Zhou L, . . . Savage SA. The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute. Cell Death Differ. May 2022;29(5):1071-1073. doi.org/10.1038/s41418-022-00976-3
• Demel UM, Boger M, Yousefian S, Grunert C, Zhang L, Hotz PW, Gottschlich A, Kose H, Isaakidis K, . . . Keller U. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. J Clin Invest. May 2 2022;132(9) doi.org/10.1172/JCI152383
• DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, . . . Jones MR. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. J Natl Cancer Inst. Nov 14 2022;114(11):1533-1544. doi.org/10.1093/jnci/djac160
• Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, Michailidou K, Bolla MK, Wang Q, . . . Breast Cancer Association C. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. Br J Sports Med. Oct 2022;56(20):1157-1170. doi.org/10.1136/bjsports-2021-105132
• Doffo J, Bamopoulos SA, Kose H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, . . . Wirth M. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. Mar 1 2022;119(9) doi.org/10.1073/pnas.2105691119
• Dohner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, . . . Lopes de Menezes D. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. Oct 13 2022;140(15):1674-1685. doi.org/10.1182/blood.2022016293
• Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, . . . Casucci M. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. May 2022;10(5) doi.org/10.1136/jitc-2021-003486
• Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonzalez-Neira A, Heijl SM, Adank MA, Ahearn TU, . . . Easton DF. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med. May 18 2022;14(1):51. doi.org/10.1186/s13073-022-01052-8
• Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsova I, . . . Ascierto PA. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. J Clin Oncol. Dec 20 2022;40(36):4178-4188. doi.org/10.1200/JCO.21.02659
• Dutzmann CM, Spix C, Popp I, Kaiser M, Erdmann F, Erlacher M, Dork T, Schindler D, Kalb R, . . . Kratz CP. Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia-A Nationwide Register-Based Cohort Study in Germany. J Clin Oncol. Jan 1 2022;40(1):32-39. doi.org/10.1200/JCO.21.01495
• Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, Burkhardt B, Classen CF, Claviez A, . . . Albert MH. Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia. Nov 2022;36(11):2567-2576. doi.org/10.1038/s41375-022-01693-z
• Elakad O, Haupl B, Labitzky V, Yao S, Kuffer S, von Hammerstein-Equord A, Danner BC, Jucker M, Urlaub H, . . . Bohnenberger H. Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. NPJ Precis Oncol. Jul 19 2022;6(1):52. doi.org/10.1038/s41698-022-00296-2
• Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, Imschweiler T, Jorch N, Pekrun A, . . . Horstmann MA. Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group. Haematologica. May 1 2022;107(5):1026-1033. doi.org/10.3324/haematol.2021.279357
• Espinet E, Klein L, Pure E, Singh SK. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer. Dec 2022;8(12):1060-1071. doi.org/10.1016/j.trecan.2022.08.005
• Falcomata C, Barthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, . . . Saur D. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. Mar 2022;3(3):318-336. doi.org/10.1038/s43018-021-00326-1
• Fernandez-Sevilla LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, Zuluaga P, Jimenez E, Sacedon R, Martinez-Sanchez MV, Jazbec J, . . . Vicente A. High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes. Blood. Jun 2 2022;139(22):3303-3313. doi.org/10.1182/blood.2021013506
• Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, . . . Pujade-Lauraine E. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol. Oct 2022;33(10):1021-1028. doi.org/10.1016/j.annonc.2022.06.011
• Frost N, Griesinger F, Hoffmann H, Langer F, Nestle U, Schutte W, Wolf J, Reck M. Lung Cancer in Germany. J Thorac Oncol. Jun 2022;17(6):742-750. doi.org/10.1016/j.jtho.2022.03.010
• Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, . . . Pinato DJ. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. Eur J Cancer. Nov 2022;175:204-213. doi.org/10.1016/j.ejca.2022.08.024
• Ganser A. Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia? Haematologica. Jul 1 2022;107(7):1496-1497. doi.org/10.3324/haematol.2021.279820
• Geyer CE, Jr., Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, . . . Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. Dec 2022;33(12):1250-1268. doi.org/10.1016/j.annonc.2022.09.159
• Giansanti P, Samaras P, Bian Y, Meng C, Coluccio A, Frejno M, Jakubowsky H, Dobiasch S, Hazarika RR, . . . Kuster B. Mass spectrometry-based draft of the mouse proteome. Nat Methods. Jul 2022;19(7):803-811. doi.org/10.1038/s41592-022-01526-y
• Gluz O, Nitz U, Kolberg-Liedtke C, Prat A, Christgen M, Kuemmel S, Mohammadian MP, Gebauer D, Kates R, . . . investigators AT. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin Cancer Res. Nov 14 2022;28(22):4995-5003. doi.org/10.1158/1078-0432.CCR-22-0482
• Graham J, Vogel A, Cheng AL, Bjarnason GA, Neal JW. Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. Cancer Treat Rev. Nov 2022;110:102453. doi.org/10.1016/j.ctrv.2022.102453
• Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, . . . Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. Eur J Cancer. Sep 2022;173:178-193. doi.org/10.1016/j.ejca.2022.06.011
• Haber AC, Sax U, Prasser F, Consortium NFH. Open tools for quantitative anonymization of tabular phenotype data: literature review. Brief Bioinform. Nov 19 2022;23(6) doi.org/10.1093/bib/bbac440
• Haupt LP, Rebs S, Maurer W, Hubscher D, Tiburcy M, Pabel S, Maus A, Kohne S, Tappu R, . . . Streckfuss-Bomeke K. Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients. Basic Res Cardiol. Mar 8 2022;117(1):13. doi.org/10.1007/s00395-022-00918-7
• Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, . . . Yakoub-Agha I. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. Mar 2022;33(3):259-275. doi.org/10.1016/j.annonc.2021.12.003
• Hermann DM, Xin W, Bahr M, Giebel B, Doeppner TR. Emerging roles of extracellular vesicle-associated non-coding RNAs in hypoxia: Insights from cancer, myocardial infarction and ischemic stroke. Theranostics. 2022;12(13):5776-5802. doi.org/10.7150/thno.73931
• Hernandez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, . . . Alentorn A. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. Feb 2023;34(2):186-199. doi.org/10.1016/j.annonc.2022.11.002
• Hillemanns P, Denecke A, Woelber L, Bohmer G, Jentschke M, Schjetne KW, Bruins Slot KMH, Fredriksen AB. A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial. Clin Cancer Res. Nov 14 2022;28(22):4885-4892. doi.org/10.1158/1078-0432.CCR-22-1927
• Hinze L, Schreek S, Zeug A, Ibrahim NK, Fehlhaber B, Loxha L, Cinar B, Ponimaskin E, Degar J, . . . Gutierrez A. Supramolecular assembly of GSK3alpha as a cellular response to amino acid starvation. Mol Cell. Aug 4 2022;82(15):2858-2870 e8. doi.org/10.1016/j.molcel.2022.05.025
• Hoes MF, Arany Z, Bauersachs J, Hilfiker-Kleiner D, Petrie MC, Sliwa K, van der Meer P. Pathophysiology and risk factors of peripartum cardiomyopathy. Nat Rev Cardiol. Aug 2022;19(8):555-565. doi.org/10.1038/s41569-021-00664-8
• Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klumpen HJ, Adeva J, Vogel A, Lleo A, . . . Banales JM. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. May 2022;76(5):1109-1121. doi.org/10.1016/j.jhep.2021.12.010
• Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, Yanir AD, Buechner J, Elhasid R, . . . Baruchel A. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. Jun 2022;36(6):1525-1532. doi.org/10.1038/s41375-022-01546-9
• Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, . . . Dohner K. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia. Sep 2022;36(9):2218-2227. doi.org/10.1038/s41375-022-01650-w
• Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, . . . Oellerich T. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. Mar 14 2022;40(3):301-317 e12. doi.org/10.1016/j.ccell.2022.02.006
• Jung CFM, Hallit R, Muller-Dornieden A, Calmels M, Goere D, Chaput U, Camus M, Gonzalez JM, Barthet M, . . . Barret M. Endoscopic internal drainage and low negative-pressure endoscopic vacuum therapy for anastomotic leaks after oncologic upper gastrointestinal surgery. Endoscopy. Jan 2022;54(1):71-74. doi.org/10.1055/a-1375-8151
• Jurmeister P, Gloss S, Roller R, Leitheiser M, Schmid S, Mochmann LH, Paya Capilla E, Fritz R, Dittmayer C, . . . Capper D. DNA methylation-based classification of sinonasal tumors. Nat Commun. Nov 28 2022;13(1):7148. doi.org/10.1038/s41467-022-34815-3
• Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V, . . . Rixecker TM. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol. Feb 2022;9(2):e133-e142. doi.org/10.1016/S2352-3026(21)00369-0
• Keck MK, Sill M, Wittmann A, Joshi P, Stichel D, Beck P, Okonechnikow K, Sievers P, Wefers AK, . . . Jones DTW. Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification. Acta Neuropathol. Jan 2023;145(1):49-69. doi.org/10.1007/s00401-022-02516-2
• Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, . . . Mandala M. Prognostic and predictive value of beta-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. Apr 2022;165:97-112. doi.org/10.1016/j.ejca.2022.01.017
• Khalil A, Wurthwein G, Golitsch J, Hempel G, Fobker M, Gerss J, Moricke A, Zimmermann M, Smisek P, . . . Lanvers-Kaminsky C. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. Jan 1 2022;107(1):49-57. doi.org/10.3324/haematol.2020.258525
• Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, . . . Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. Jul 2022;36(7):1703-1719. doi.org/10.1038/s41375-022-01613-1
• Klumper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, Sikic D, Breyer J, . . . Eckstein M. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res. Apr 14 2023;29(8):1496-1505. doi.org/10.1158/1078-0432.CCR-22-1764
• Kochanek M, Kochanek J, Boll B, Eichenauer DA, Beutel G, Bracht H, Braune S, Eisner F, Friesecke S, . . . Shimabukuro-Vornhagen A. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis. Intensive Care Med. Mar 2022;48(3):332-342. doi.org/10.1007/s00134-022-06635-y
• Kratz CP, Smirnov D, Autry R, Jager N, Waszak SM, Grosshennig A, Berutti R, Wendorff M, Hainaut P, . . . Malkin D. Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer. J Natl Cancer Inst. Nov 14 2022;114(11):1523-1532. doi.org/10.1093/jnci/djac151
• Krauss L, Urban BC, Hastreiter S, Schneider C, Wenzel P, Hassan Z, Wirth M, Lankes K, Terrasi A, . . . Schneider G. HDAC2 Facilitates Pancreatic Cancer Metastasis. Cancer Res. Feb 15 2022;82(4):695-707. doi.org/10.1158/0008-5472.CAN-20-3209
• Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, . . . Investigators K-. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. May 2022;167:1-12. doi.org/10.1016/j.ejca.2022.02.009
• Latif MU, Schmidt GE, Mercan S, Rahman R, Gibhardt CS, Stejerean-Todoran I, Reutlinger K, Hessmann E, Singh SK, . . . Ellenrieder V. NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut. Dec 2022;71(12):2561-2573. doi.org/10.1136/gutjnl-2021-325013
• Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, Lee A, Yang X, . . . Antoniou AC. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol. May 10 2022;40(14):1529-1541. doi.org/10.1200/JCO.21.02112
• Linnemannstons K, Karuna MP, Witte L, Choezom D, Honemann-Capito M, Lagurin AS, Schmidt CV, Shrikhande S, Steinmetz LK, . . . Gross JC. Microscopic and biochemical monitoring of endosomal trafficking and extracellular vesicle secretion in an endogenous in vivo model. J Extracell Vesicles. Sep 2022;11(9):e12263. doi.org/10.1002/jev2.12263
• Liu Y, Banka S, Huang Y, Hardman-Smart J, Pye D, Torrelo A, Beaman GM, Kazanietz MG, Baker MJ, . . . Zhang X. Germline intergenic duplications at Xq26.1 underlie Bazex-Dupre-Christol basal cell carcinoma susceptibility syndrome. Br J Dermatol. Dec 2022;187(6):948-961. doi.org/10.1111/bjd.21842
• Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC, clinicalguidelines@esmo.org EGCEa. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. Oct 2022;33(10):1005-1020. doi.org/10.1016/j.annonc.2022.07.004
• Lu D, Chatterjee S, Xiao K, Riedel I, Huang CK, Costa A, Cushman S, Neufeldt D, Rode L, . . . Thum T. A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. Eur Heart J. Nov 7 2022;43(42):4496-4511. doi.org/10.1093/eurheartj/ehac337
• Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, . . . Group ESCSD. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. Nov 1 2022;43(41):4229-4361. doi.org/10.1093/eurheartj/ehac244
• Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, Ruf B, Brown Z, Heinrich B, . . . Greten TF. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. Sep 12 2022;40(9):986-998 e5. doi.org/10.1016/j.ccell.2022.08.004
• Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, . . . Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol. Oct 2022;77(4):1161-1197. doi.org/10.1016/j.jhep.2022.07.008
• Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, . . . Strobel P. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? J Thorac Oncol. Feb 2022;17(2):200-213. doi.org/10.1016/j.jtho.2021.10.010
• Melzer MK, Breunig M, Arnold F, Wezel F, Azoitei A, Roger E, Kruger J, Merkle J, Schutte L, . . . Kleger A. Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. Adv Healthc Mater. Jun 2022;11(11):e2102345. doi.org/10.1002/adhm.202102345
• Mitteldorf C. Multistaining for a better understanding of lymphoma biology. Br J Dermatol. Aug 2022;187(2):139-140. doi.org/10.1111/bjd.21590
• Modest DP, Karthaus M, Fruehauf S, Graeven U, Muller L, Konig AO, Fischer von Weikersthal L, Caca K, Kretzschmar A, . . . Trarbach T. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol. Jan 1 2022;40(1):72-82. doi.org/10.1200/JCO.21.01332
• Moker P, Zur Stadt U, Zimmermann M, Alawi M, Mueller S, Finger J, Knorr F, Riquelme A, Oschlies I, . . . Damm-Welk C. Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia. Leukemia. Sep 2022;36(9):2343-2346. doi.org/10.1038/s41375-022-01626-w
• Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, . . . Dohner H. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. Apr 21 2022;386(16):1519-1531. doi.org/10.1056/NEJMoa2117344
• Muller K, Vogiatzi F, Winterberg D, Rosner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MP, Bruggemann M, . . . Schewe DM. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood. Jul 7 2022;140(1):45-57. doi.org/10.1182/blood.2021014485
• Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhauser M, Stelljes M, Finke J, Ganser A, Einsele H, . . . Mohty M. Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. Clin Cancer Res. Oct 3 2022;28(19):4258-4266. doi.org/10.1158/1078-0432.CCR-22-0809
• Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, Buettner F, Conche C, Petrocelli V, . . . Greten FR. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. Feb 14 2022;40(2):168-184 e13. doi.org/10.1016/j.ccell.2022.01.004
• Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, . . . investigators W-A. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. May 2022;23(5):625-635. doi.org/10.1016/S1470-2045(22)00159-0
• Nitz UA, Gluz O, Kummel S, Christgen M, Braun M, Aktas B, Ludtke-Heckenkamp K, Forstbauer H, Grischke EM, . . . Harbeck N. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. J Clin Oncol. Aug 10 2022;40(23):2557-2567. doi.org/10.1200/JCO.21.02759
• Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC, . . . clinicalguidelines@esmo.org EGCEa. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. Oct 2022;33(10):992-1004. doi.org/10.1016/j.annonc.2022.07.003
• Oswald E, Bug D, Grote A, Lashuk K, Bouteldja N, Lenhard D, Lohr A, Behnke A, Knauff V, . . . Schueler J. Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up. J Immunother Cancer. Apr 2022;10(4) doi.org/10.1136/jitc-2021-004412
• Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, Preece R, Chu J, Kubat A, . . . group TC-C. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. Oct 26 2022;14(668):eabq3010. doi.org/10.1126/scitranslmed.abq3010
• Palus S, Elkina Y, Braun T, von Haehling S, Dohner W, Anker SD, Cerami A, Brines M, Springer J. The erythropoietin-derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle. Aug 2022;13(4):2202-2210. doi.org/10.1002/jcsm.13009
• Paprocka R, Wiese-Szadkowska M, Janciauskiene S, Kosmalski T, Kulik M, Helmin-Basa A. Latest developments in metal complexes as anticancer agents. Coordination Chemistry Reviews. 2022;452 doi.org/10.1016/j.ccr.2021.214307
• Penkert J, Struwe FJ, Dutzmann CM, Doergeloh BB, Montellier E, Freycon C, Keymling M, Schlemmer HP, Sanger B, . . . Kratz CP. Genotype-phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry. J Hematol Oncol. Aug 16 2022;15(1):107. doi.org/10.1186/s13045-022-01332-1
• Peschke K, Jakubowsky H, Schafer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, . . . Reichert M. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med. Apr 7 2022;14(4):e14876. doi.org/10.15252/emmm.202114876
• Peterziel H, Jamaladdin N, ElHarouni D, Gerloff XF, Herter S, Fiesel P, Berker Y, Blattner-Johnson M, Schramm K, . . . Oehme I. Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM. NPJ Precis Oncol. Dec 27 2022;6(1):94. doi.org/10.1038/s41698-022-00335-y
• Pfeifer R, Henze J, Wittich K, Gosselink A, Kinkhabwala A, Gremse F, Bleilevens C, Bigott K, Jungblut M, . . . Al Rawashdeh W. A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level. Theranostics. 2022;12(11):4834-4850. doi.org/10.7150/thno.68966
• Pfister SM, Reyes-Mugica M, Chan JKC, Hasle H, Lazar AJ, Rossi S, Ferrari A, Jarzembowski JA, Pritchard-Jones K, . . . Alaggio R. A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discov. Feb 2022;12(2):331-355. doi.org/10.1158/2159-8290.CD-21-1094
• Platzbecker U, Gotze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, . . . Giagounidis A. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study. J Clin Oncol. Nov 20 2022;40(33):3800-3807. doi.org/10.1200/JCO.21.02476
• Rabold K, Zoodsma M, Grondman I, Kuijpers Y, Bremmers M, Jaeger M, Zhang B, Hobo W, Bonenkamp HJ, . . . Netea-Maier RT. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat Commun. Oct 18 2022;13(1):6149. doi.org/10.1038/s41467-022-33907-4
• Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, Hubschmann D, Toprak UH, . . . Heppner FL. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. May 10 2022;13(1):2558. doi.org/10.1038/s41467-022-30050-y
• Rasmussen B, Gohring G, Bernard E, Nilsson L, Tobiasson M, Jadersten M, Garelius H, Dybedal I, Gronbaek K, . . . Hellstrom-Lindberg E. "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)". Leukemia. May 2022;36(5):1436-1439. doi.org/10.1038/s41375-022-01537-w
• Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, . . . Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. Mar 2022;76(3):681-693. doi.org/10.1016/j.jhep.2021.11.018
• Ren H, Bosch F, Pretzsch E, Jacob S, Westphalen CB, Walter Holch J, Werner J, Angele MK. Identification of an EMT-related Gene Signature Predicting Recurrence in Stage II/III Colorectal Cancer: A Retrospective Study in 1780 Patients. Ann Surg. Nov 1 2022;276(5):897-904. doi.org/10.1097/SLA.0000000000005644
• Richter-Pechanska P, Kunz JB, Rausch T, Erarslan-Uysal B, Bornhauser B, Frismantas V, Assenov Y, Zimmermann M, Happich M, . . . Kulozik AE. Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. Leukemia. Jul 2022;36(7):1759-1768. doi.org/10.1038/s41375-022-01587-0
• Rieken S. Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases. Lancet Oncol. Jul 2022;23(7):832-833. doi.org/10.1016/S1470-2045(22)00301-1
• Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, . . . Dohner H. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. Apr 7 2022;139(14):2145-2155. doi.org/10.1182/blood.2021013404
• Rucker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, . . . Dohner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. Jan 2022;36(1):90-99. doi.org/10.1038/s41375-021-01323-0
• Ruhlmann F, Tichelbacker T, Mackert AF, Engelhardt D, Leha A, Bernhardt M, Ghadimi M, Perl T, Azizian A, . . . Gaedcke J. Incidence, Associated Risk Factors, and Outcomes of Postoperative Arrhythmia After Upper Gastrointestinal Surgery. JAMA Netw Open. Jul 1 2022;5(7):e2223225. doi.org/10.1001/jamanetworkopen.2022.23225
• Saborowski A, Vogel A, Segatto O. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Trends Cancer. Feb 2022;8(2):83-86. doi.org/10.1016/j.trecan.2021.11.001
• Sandmann L, Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed. Hepatology. May 2022;75(5):1075-1077. doi.org/10.1002/hep.32333
• Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, . . . Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. Feb 2022;76(2):353-363. doi.org/10.1016/j.jhep.2021.09.035
• Schick M, Zhang L, Maurer S, Maurer HC, Isaakaidis K, Schneider L, Patra U, Schunck K, Rohleder E, . . . Keller U. Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma. Nat Commun. Jan 12 2022;13(1):281. doi.org/10.1038/s41467-021-27704-8
• Schneeweis C, Hassan Z, Ascherl K, Wirth M, Koutsouli S, Orben F, Krauss L, Schneider C, Ollinger R, . . . Schneider G. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Cancer Commun (Lond). Apr 2022;42(4):360-364. doi.org/10.1002/cac2.12280
• Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Dohner K, Perner F, Eifert T, Huber N, . . . Heidel FH. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. Feb 17 2022;139(7):1080-1097. doi.org/10.1182/blood.2021012778
• Schubert A, Voloshanenko O, Ragaller F, Gmach P, Kranz D, Scheeder C, Miersch T, Schulz M, Trumper L, . . . Boutros M. Superresolution microscopy localizes endogenous Dvl2 to Wnt signaling-responsive biomolecular condensates. Proc Natl Acad Sci U S A. Jul 26 2022;119(30):e2122476119. doi.org/10.1073/pnas.2122476119
• Sies K, Winkler JK, Fink C, Bardehle F, Toberer F, Buhl T, Enk A, Blum A, Stolz W, . . . Haenssle HA. Does sex matter? Analysis of sex-related differences in the diagnostic performance of a market-approved convolutional neural network for skin cancer detection. Eur J Cancer. Mar 2022;164:88-94. doi.org/10.1016/j.ejca.2021.12.034
• Solvie D, Baluapuri A, Uhl L, Fleischhauer D, Endres T, Papadopoulos D, Aziba A, Gaballa A, Mikicic I, . . . Eilers M. MYC multimers shield stalled replication forks from RNA polymerase. Nature. Dec 2022;612(7938):148-155. doi.org/10.1038/s41586-022-05469-4
• Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Muller T, Vydzhak O, Symeonidis K, Crispatzu G, . . . Herling M. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Blood. Mar 23 2023;141(12):1425-1441. doi.org/10.1182/blood.2022015494
• Stejerean-Todoran I, Gimotty PA, Watters A, Brafford P, Krepler C, Godok T, Li H, Bonilla Del Rio Z, Zieseniss A, . . . Vultur A. A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells. Neuro Oncol. Apr 6 2023;25(4):674-686. doi.org/10.1093/neuonc/noac212
• Suwala AK, Felix M, Friedel D, Stichel D, Schrimpf D, Hinz F, Hewer E, Schweizer L, Dohmen H, . . . Reuss DE. Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathol. Feb 2022;143(2):263-281. doi.org/10.1007/s00401-021-02395-z
• Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, . . . Papaemmanuil E. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Commun. Aug 8 2022;13(1):4622. doi.org/10.1038/s41467-022-32103-8
• Thielmann CM, Matull J, Zaremba A, Murali R, Chorti E, Lodde G, Jansen P, Herbst R, Terheyden P, . . . Griewank KG. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. Eur J Cancer. Jan 2022;161:99-107. doi.org/10.1016/j.ejca.2021.11.009
• Thol F. Fusion genes in acute myeloid leukemia: do acute myeloid leukemia diagnostics need to fuse with RNA-sequencing? Haematologica. Jan 1 2022;107(1):44-45. doi.org/10.3324/haematol.2021.278983
• Toksvang LN, Grell K, Nersting J, Degn M, Nielsen SN, Abrahamsson J, Lund B, Kanerva J, Jonsson OG, . . . Schmiegelow K. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis. Leukemia. Jan 2022;36(1):33-41. doi.org/10.1038/s41375-021-01182-9
• Tsai JW, Cejas P, Wang DK, Patel S, Wu DW, Arounleut P, Wei X, Zhou N, Syamala S, . . . Phoenix TN. FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. Cancer Res. Sep 2 2022;82(17):2980-3001. doi.org/10.1158/0008-5472.CAN-22-0671
• Vergote I, Gonzalez-Martin A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, . . . European experts' consensus g. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. Mar 2022;33(3):276-287. doi.org/10.1016/j.annonc.2021.11.013
• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. Oct 15 2022;400(10360):1345-1362. doi.org/10.1016/S0140-6736(22)01200-4
• Vogel A, Saborowski A. Medical therapy of HCC. J Hepatol. Jan 2022;76(1):208-210. doi.org/10.1016/j.jhep.2021.05.017
• Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, . . . Tiu RV. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. Oct 27 2022;140(17):1845-1857. doi.org/10.1182/blood.2021014586
• Weber-Lassalle K, Ernst C, Reuss A, Mollenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, . . . Hahnen E. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. J Natl Cancer Inst. Apr 11 2022;114(4):565-570. doi.org/10.1093/jnci/djab231
• Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona MA, Kandulski A, Jeliazkova P, Best J, . . . Vogel A. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study. Liver Cancer. Jun 2022;11(3):219-232. doi.org/10.1159/000521746
• Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, . . . Oellerich T. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. Jan 27 2022;139(4):538-553. doi.org/10.1182/blood.2021012081
• Wimberger P, Gerber MJ, Pfisterer J, Erdmann K, Fussel S, Link T, du Bois A, Kommoss S, Heitz F, . . . Kuhlmann JD. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant. Clin Cancer Res. Nov 1 2022;28(21):4660-4668. doi.org/10.1158/1078-0432.CCR-22-1326
• Yang M, Pan Z, Huang K, Busche G, Liu H, Gohring G, Rumpel R, Dittrich-Breiholz O, Talbot S, . . . Li Z. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. Leukemia. Mar 2022;36(3):675-686. doi.org/10.1038/s41375-021-01452-6
• Yuan L, Springer J, Palus S, Busquets S, Jove Q, Alves de Lima Junior E, Anker MS, von Haehling S, Alvarez Ladron N, . . . Argiles JM. The atypical beta-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. J Cachexia Sarcopenia Muscle. Feb 2023;14(1):653-660. doi.org/10.1002/jcsm.13116
• Zhang R, Shen S, Wei Y, Zhu Y, Li Y, Chen J, Guan J, Pan Z, Wang Y, . . . Christiani DC. A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians. J Thorac Oncol. Aug 2022;17(8):974-990. doi.org/10.1016/j.jtho.2022.04.011
• Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duhrsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, . . . Trappe RU. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia. Oct 2022;36(10):2468-2478. doi.org/10.1038/s41375-022-01667-1
• Zippel S, Dilger N, Chatterjee C, Raic A, Brenner-Weiss G, Schadzek P, Rapp BE, Lee-Thedieck C. A parallelized, perfused 3D triculture model of leukemia forin vitrodrug testing of chemotherapeutics. Biofabrication. May 17 2022;14(3) doi.org/10.1088/1758-5090/ac6a7e
• Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, Fronkova E, Alten J, Koehler R, . . . Cario G. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. Dec 2022;36(12):2793-2801. doi.org/10.1038/s41375-022-01668-0

2021

• Abdin SM, Paasch D, Morgan M, Lachmann N. CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. J Immunother Cancer. Aug 2021;9(8) doi.org/10.1136/jitc-2021-002741
• Alhalabi KT, Stichel D, Sievers P, Peterziel H, Sommerkamp AC, Sturm D, Wittmann A, Sill M, Jager N, . . . Jones DTW. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathol. Nov 2021;142(5):841-857. doi.org/10.1007/s00401-021-02354-8
• Anker MS, von Haehling S, Coats AJS, Riess H, Eucker J, Porthun J, Butler J, Karakas M, Haverkamp W, . . . Anker SD. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. Eur J Heart Fail. Jan 2021;23(1):145-153. doi.org/10.1002/ejhf.2059
• Arbyn M, Simon M, Peeters E, Xu L, Meijer C, Berkhof J, Cuschieri K, Bonde J, Ostrbenk Vanlencak A, . . . Poljak M. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. Aug 2021;27(8):1083-1095. doi.org/10.1016/j.cmi.2021.04.031
• Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, Fachal L, Michailidou K, Bolla MK, . . . Fletcher O. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. Am J Hum Genet. Jul 1 2021;108(7):1190-1203. doi.org/10.1016/j.ajhg.2021.05.013
• Behrens YL, Gohring G, Bawadi R, Coktu S, Reimer C, Hoffmann B, Sanger B, Kafer S, Thol F, . . . Kratz CP. A novel classification of hematologic conditions in patients with Fanconi anemia. Haematologica. Nov 1 2021;106(11):3000-3003. doi.org/10.3324/haematol.2021.279332
• Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, Filliol A, Chin L, Savage TM, . . . Schwabe RF. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. Jun 1 2021;131(11) doi.org/10.1172/JCI146987
• Boer JM, Valsecchi MG, Hormann FM, Antic Z, Zaliova M, Schwab C, Cazzaniga G, Arfeuille C, Cave H, . . . Pieters R. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia. Oct 2021;35(10):2978-2982. doi.org/10.1038/s41375-021-01333-y
• Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Munch V, Sun Q, . . . Meyer LH. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood. Nov 18 2021;138(20):1953-1965. doi.org/10.1182/blood.2020007591
• Borchert F, Mock A, Tomczak A, Hugel J, Alkarkoukly S, Knurr A, Volckmar AL, Stenzinger A, Schirmacher P, . . . Schapranow MP. Knowledge bases and software support for variant interpretation in precision oncology. Brief Bioinform. Nov 5 2021;22(6) doi.org/10.1093/bib/bbab134
• Bottomley A, Coens C, Mierzynska J, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, . . . Group EM. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. May 2021;22(5):655-664. doi.org/10.1016/S1470-2045(21)00081-4
• Breast Cancer Association C, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, Parsons MT, . . . Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. Feb 4 2021;384(5):428-439. doi.org/10.1056/NEJMoa1913948
• Bufe A, Garcia Del Arco A, Hennecke M, de Jaime-Soguero A, Ostermaier M, Lin YC, Ciprianidis A, Hattemer J, Engel U, . . . Acebron SP. Wnt signaling recruits KIF2A to the spindle to ensure chromosome congression and alignment during mitosis. Proc Natl Acad Sci U S A. Aug 24 2021;118(34) doi.org/10.1073/pnas.2108145118
• Cappello S, Sung HM, Ickes C, Gibhardt CS, Vultur A, Bhat H, Hu Z, Brafford P, Denger A, . . . Bogeski I. Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies. Cancer Res. Nov 1 2021;81(21):5540-5554. doi.org/10.1158/0008-5472.CAN-21-0164
• Chatterjee S, Hofer T, Costa A, Lu D, Batkai S, Gupta SK, Bolesani E, Zweigerdt R, Megias D, . . . Bar C. Telomerase therapy attenuates cardiotoxic effects of doxorubicin. Mol Ther. Apr 7 2021;29(4):1395-1410. doi.org/10.1016/j.ymthe.2020.12.035
• Chaturvedi A, Gupta C, Gabdoulline R, Borchert NM, Goparaju R, Kaulfuss S, Gorlich K, Schottmann R, Othman B, . . . Heuser M. Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica. Feb 1 2021;106(2):565-573. doi.org/10.3324/haematol.2019.236992
• Chereda H, Bleckmann A, Menck K, Perera-Bel J, Stegmaier P, Auer F, Kramer F, Leha A, Beissbarth T. Explaining decisions of graph convolutional neural networks: patient-specific molecular subnetworks responsible for metastasis prediction in breast cancer. Genome Med. Mar 11 2021;13(1):42. doi.org/10.1186/s13073-021-00845-7
• Cibula D, Dostalek L, Hillemanns P, Scambia G, Jarkovsky J, Persson J, Raspagliesi F, Novak Z, Jaeger A, . . . Runnenbaum I. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. Eur J Cancer. Jan 2021;143:88-100. doi.org/10.1016/j.ejca.2020.10.037
• Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, . . . Antoniou AC. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. May 14 2021;12(1):2986. doi.org/10.1038/s41467-021-23162-4
• Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. Apr 2021;74(4):944-951. doi.org/10.1016/j.jhep.2021.01.032
• Croci GA, Au-Yeung RKH, Reinke S, Staiger AM, Koch K, Oschlies I, Richter J, Poeschel V, Held G, . . . Klapper W. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status. Ann Oncol. Nov 2021;32(11):1400-1409. doi.org/10.1016/j.annonc.2021.08.1991
• Dannenmann B, Klimiankou M, Oswald B, Solovyeva A, Mardan J, Nasri M, Ritter M, Zahabi A, Arreba-Tutusaus P, . . . Skokowa J. iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia. Cell Stem Cell. May 6 2021;28(5):906-922 e6. doi.org/10.1016/j.stem.2021.03.023
• Decker M, Lammens T, Ferster A, Erlacher M, Yoshimi A, Niemeyer CM, Ernst MPT, Raaijmakers M, Duployez N, . . . Ripperger T. Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies. Leukemia. Nov 2021;35(11):3304-3308. doi.org/10.1038/s41375-021-01200-w
• Deng MY, Sturm D, Pfaff E, Sill M, Stichel D, Balasubramanian GP, Tippelt S, Kramm C, Donson AM, . . . Jones DTW. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. Nat Commun. Sep 20 2021;12(1):5530. doi.org/10.1038/s41467-021-25708-y
• Derlin T, Krischke E, Ross TL, Bengel FM. Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment. Eur J Nucl Med Mol Imaging. Sep 2021;48(10):3343-3344. doi.org/10.1007/s00259-021-05335-x
• Durno C, Ercan AB, Bianchi V, Edwards M, Aronson M, Galati M, Atenafu EG, Abebe-Campino G, Al-Battashi A, . . . Tabori U. Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. J Clin Oncol. Sep 1 2021;39(25):2779-2790. doi.org/10.1200/JCO.20.02636
• Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, Revesz T, Hoogerbrugge P, Hancock J, . . . Saha V. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. Jul 2021;151:175-189. doi.org/10.1016/j.ejca.2021.03.034
• Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, Gabrysch A, Warnatz K, Goldacker S, . . . Grimbacher B. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. Feb 2022;149(2):736-746. doi.org/10.1016/j.jaci.2021.04.039
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, . . . Group EM. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. May 2021;22(5):643-654. doi.org/10.1016/S1470-2045(21)00065-6
• Falcomata C, Barthel S, Ulrich A, Diersch S, Veltkamp C, Rad L, Boniolo F, Solar M, Steiger K, . . . Saur D. Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer. Cancer Discov. Dec 1 2021;11(12):3158-3177. doi.org/10.1158/2159-8290.CD-21-0209
• Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, Rossi D, Filip I, Pan-Hammarstrom Q, . . . Dalla-Favera R. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. Jun 1 2021;118(22) doi.org/10.1073/pnas.2104504118
• Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U, clinicalguidelines@esmo.org EGCEa. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger☆). Ann Oncol. Feb 2021;32(2):142-156. doi.org/10.1016/j.annonc.2020.11.002
• Feurstein S, Churpek JE, Walsh T, Keel S, Hakkarainen M, Schroeder T, Germing U, Geyh S, Heuser M, . . . Godley LA. Germline variants drive myelodysplastic syndrome in young adults. Leukemia. Aug 2021;35(8):2439-2444. doi.org/10.1038/s41375-021-01137-0
• Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, . . . Evans TRJ. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study. Clin Cancer Res. Sep 1 2021;27(17):4848-4858. doi.org/10.1158/1078-0432.CCR-20-4219
• Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, Rullier E, Smith JJ, Marijnen C, . . . Rodel C. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. Dec 2021;18(12):805-816. doi.org/10.1038/s41571-021-00538-5
• Forster A, Brand F, Banan R, Huneburg R, Weber CAM, Ewert W, Kronenberg J, Previti C, Elyan N, . . . Weber RG. Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin. Acta Neuropathol. Jul 2021;142(1):191-210. doi.org/10.1007/s00401-021-02307-1
• Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, Sander P, Baptista MJ, Heming JN, . . . Lenz G. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. Aug 31 2021;12(1):5183. doi.org/10.1038/s41467-021-25405-w
• Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Haenel M, Truemper L, Held G, Bentz M, . . . Schmitz N. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. Apr 2021;8(4):e267-e277. doi.org/10.1016/S2352-3026(21)00022-3
• Ganser A. What can Heraclitus tell us about AML? Blood. May 20 2021;137(20):2719-2720. doi.org/10.1182/blood.2021011264
• Gelmon KA, Fasching PA, Couch FJ, Balmana J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, . . . Collaborating I. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer. Jul 2021;152:68-77. doi.org/10.1016/j.ejca.2021.03.029
• Giesen N, Sprute R, Ruthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, . . . Medical O. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. Apr 2021;147:154-160. doi.org/10.1016/j.ejca.2021.01.033
• Gogas H, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, . . . Flaherty KT. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer. Jul 2021;152:116-128. doi.org/10.1016/j.ejca.2021.04.028
• Goli R, Li J, Brandimarto J, Levine LD, Riis V, McAfee Q, DePalma S, Haghighi A, Seidman JG, . . . Arany Z. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. May 11 2021;143(19):1852-1862. doi.org/10.1161/CIRCULATIONAHA.120.052395
• Gout J, Perkhofer L, Morawe M, Arnold F, Ihle M, Biber S, Lange S, Roger E, Kraus JM, . . . Kleger A. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut. Apr 2021;70(4):743-760. doi.org/10.1136/gutjnl-2019-319970
• Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, . . . Harbeck N. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J Immunother Cancer. May 2021;9(5) doi.org/10.1136/jitc-2020-002198
• Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, . . . Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. Mar 11 2021;137(10):1353-1364. doi.org/10.1182/blood.2020006464
• Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pfohler C, Loquai C, Ruini C, Utikal J, . . . German Dermatooncology G. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. Eur J Cancer. May 2021;149:1-10. doi.org/10.1016/j.ejca.2021.02.017
• Haenssle HA, Winkler JK, Fink C, Toberer F, Enk A, Stolz W, Deinlein T, Hofmann-Wellenhof R, Kittler H, . . . level IIGCA. Skin lesions of face and scalp - Classification by a market-approved convolutional neural network in comparison with 64 dermatologists. Eur J Cancer. Feb 2021;144:192-199. doi.org/10.1016/j.ejca.2020.11.034
• Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, . . . monarch ECM. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. Dec 2021;32(12):1571-1581. doi.org/10.1016/j.annonc.2021.09.015
• Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, . . . Investigators DI. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. Dec 2 2021;385(23):2123-2131. doi.org/10.1056/NEJMoa2103294
• Hasanali SL, Morera DS, Racine RR, Hennig M, Ghosh S, Lopez LE, Hupe MC, Escudero DO, Wang J, . . . Lokeshwar VB. HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer. Clin Cancer Res. Aug 1 2021;27(15):4410-4421. doi.org/10.1158/1078-0432.CCR-21-0422
• Herkt M, Thum T. Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics. Mol Ther. Feb 3 2021;29(2):521-539. doi.org/10.1016/j.ymthe.2020.11.008
• Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, . . . Cloos J. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. Dec 30 2021;138(26):2753-2767. doi.org/10.1182/blood.2021013626
• Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Moricke A, Boer JM, Cave H, Cazzaniga G, . . . Manabe A. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. Nov 2021;35(11):3272-3277. doi.org/10.1038/s41375-021-01199-0
• Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, . . . Cutaneous Lymphoma International Consortium i. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol. Mar 2021;184(3):524-531. doi.org/10.1111/bjd.19303
• Hol JA, Jewell R, Chowdhury T, Duncan C, Nakata K, Oue T, Gauthier-Villars M, Littooij AS, Kaneko Y, . . . Jongmans MCJ. Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. Eur J Cancer. Aug 2021;153:51-63. doi.org/10.1016/j.ejca.2021.05.014
• Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, . . . Brown AL. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. Nov 1 2021;106(11):3004-3007. doi.org/10.3324/haematol.2021.278762
• Hopfner F, Mohn N, Eiz-Vesper B, Maecker-Kolhoff B, Gottlieb J, Blasczyk R, Mahmoudi N, Pars K, Adams O, . . . Skripuletz T. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm. Jul 2021;8(4) doi.org/10.1212/NXI.0000000000001020
• Hubschmann D, Kleinheinz K, Wagener R, Bernhart SH, Lopez C, Toprak UH, Sungalee S, Ishaque N, Kretzmer H, . . . Siebert R. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. Leukemia. Jul 2021;35(7):2002-2016. doi.org/10.1038/s41375-021-01251-z
• Hughes BGM, Munoz-Couselo E, Mortier L, Bratland A, Gutzmer R, Roshdy O, Gonzalez Mendoza R, Schachter J, Arance A, . . . Grob JJ. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. Oct 2021;32(10):1276-1285. doi.org/10.1016/j.annonc.2021.07.008
• Hung RJ, Warkentin MT, Brhane Y, Chatterjee N, Christiani DC, Landi MT, Caporaso NE, Liu G, Johansson M, . . . Amos CI. Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. Cancer Res. Mar 15 2021;81(6):1607-1615. doi.org/10.1158/0008-5472.CAN-20-1237
• Isermann T, Sener OC, Stender A, Klemke L, Winkler N, Neesse A, Li J, Wegwitz F, Moll UM, . . . Schulz-Heddergott R. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nat Commun. Jun 29 2021;12(1):4019. doi.org/10.1038/s41467-021-24064-1
• Karch A, Schindler D, Kuhn-Steven A, Blaser R, Kuhn KA, Sandmann L, Sommerer C, Guba M, Heemann U, . . . for the Transplant Cohort of the German Center for Infection Research C. The transplant cohort of the German center for infection research (DZIF Tx-Cohort): study design and baseline characteristics. Eur J Epidemiol. Feb 2021;36(2):233-241. doi.org/10.1007/s10654-020-00715-3
• Kargapolova Y, Rehimi R, Kayserili H, Bruhl J, Sofiadis K, Zirkel A, Palikyras S, Mizi A, Li Y, . . . Papantonis A. Overarching control of autophagy and DNA damage response by CHD6 revealed by modeling a rare human pathology. Nat Commun. May 21 2021;12(1):3014. doi.org/10.1038/s41467-021-23327-1
• Kattih B, Shirvani A, Klement P, Garrido AM, Gabdoulline R, Liebich A, Brandes M, Chaturvedi A, Seeger T, . . . Heuser M. IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. Leukemia. May 2021;35(5):1301-1316. doi.org/10.1038/s41375-020-01043-x
• Kendre G, Marhenke S, Lorz G, Becker D, Reineke-Plaass T, Poth T, Murugesan K, Kuhnel F, Woller N, . . . Saborowski A. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma. Hepatology. Sep 2021;74(3):1357-1370. doi.org/10.1002/hep.31799
• Khanam T, Sandmann S, Seggewiss J, Ruether C, Zimmermann M, Norvil AB, Bartenhagen C, Randau G, Mueller S, . . . Burkhardt B. Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. Apr 29 2021;137(17):2347-2359. doi.org/10.1182/blood.2020005381
• Kirchhoff H, Karsli U, Schoenherr C, Battmer K, Erschow S, Talbot SR, Steinemann D, Heuser M, Heidenreich O, . . . Scherr M. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. May 13 2021;137(19):2657-2661. doi.org/10.1182/blood.2020008544
• Klumper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, Hoffmann MJ, Niegisch G, Uhlig A, . . . Dietrich D. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. Aug 2021;9(8) doi.org/10.1136/jitc-2021-002949
• Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, . . . Zimmer L. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. Eur J Cancer. May 2021;148:61-75. doi.org/10.1016/j.ejca.2021.01.034
• Knorr F, Zimmermann M, Attarbaschi A, Kabickova E, Maecker-Kolhoff B, Ruf S, Kuhnle I, Ebinger M, Garthe AK, . . . Woessmann W. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. Haematologica. Dec 1 2021;106(12):3232-3235. doi.org/10.3324/haematol.2021.278971
• Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, . . . von Deimling A. Sarcoma classification by DNA methylation profiling. Nat Commun. Jan 21 2021;12(1):498. doi.org/10.1038/s41467-020-20603-4
• Komoll RM, Hu Q, Olarewaju O, von Dohlen L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, . . . Balakrishnan A. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. Jan 2021;74(1):122-134. doi.org/10.1016/j.jhep.2020.07.039
• Kosanke M, Osetek K, Haase A, Wiehlmann L, Davenport C, Schwarzer A, Adams F, Kleppa MJ, Schambach A, . . . Martin U. Reprogramming enriches for somatic cell clones with small-scale mutations in cancer-associated genes. Mol Ther. Aug 4 2021;29(8):2535-2553. doi.org/10.1016/j.ymthe.2021.04.007
• Kosinsky RL, Zerche M, Kutschat AP, Nair A, Ye Z, Saul D, von Heesen M, Friton JJ, Schwarzer AC, . . . Johnsen SA. RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease. Cell Death Differ. Nov 2021;28(11):3161-3175. doi.org/10.1038/s41418-021-00808-w
• Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, Hohenberger W, Arnold D, . . . of the German Rectal Cancer Study G. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. Eur J Cancer. Feb 2021;144:281-290. doi.org/10.1016/j.ejca.2020.11.029
• Kostyszyn D, Fechter T, Bartl N, Grosu AL, Gratzke C, Sigle A, Mix M, Ruf J, Fassbender TF, . . . Zamboglou C. Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. J Nucl Med. Jun 1 2021;62(6):823-828. doi.org/10.2967/jnumed.120.254623
• Kozyra EJ, Gohring G, Hickstein DD, Calvo KR, DiNardo CD, Dworzak M, de Haas V, Stary J, Hasle H, . . . Wlodarski MW. Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood. Dec 9 2021;138(23):2441-2445. doi.org/10.1182/blood.2021012781
• Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, Achatz MI, Savage SA, Weitzel JN, . . . Malkin D. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol. Dec 1 2021;7(12):1800-1805. doi.org/10.1001/jamaoncol.2021.4398
• Kratz CP, Jongmans MC, Cave H, Wimmer K, Behjati S, Guerrini-Rousseau L, Milde T, Pajtler KW, Golmard L, . . . Bourdeaut F. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. Feb 2021;5(2):142-154. doi.org/10.1016/S2352-4642(20)30275-3
• Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, . . . Platzbecker U. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. Oct 20 2021;39(30):3318-3327. doi.org/10.1200/JCO.20.02724
• Kunzke T, Prade VM, Buck A, Sun N, Feuchtinger A, Matzka M, Fernandez IE, Wuyts W, Ackermann M, . . . Walch A. Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology. Cancer Res. Dec 1 2021;81(23):5862-5875. doi.org/10.1158/0008-5472.CAN-21-1175
• Kutschat AP, Hamdan FH, Wang X, Wixom AQ, Najafova Z, Gibhardt CS, Kopp W, Gaedcke J, Strobel P, . . . Johnsen SA. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer. Cancer Res. Jun 1 2021;81(11):2943-2955. doi.org/10.1158/0008-5472.CAN-20-2874
• Larose H, Prokoph N, Matthews JD, Schlederer M, Hogler S, Alsulami AF, Ducray SP, Nuglozeh E, Fazaludeen FMS, . . . Turner SD. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. Jun 1 2021;106(6):1693-1704. doi.org/10.3324/haematol.2019.238766
• Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, . . . Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. Sep 2021;35(9):2539-2551. doi.org/10.1038/s41375-021-01179-4
• Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, . . . Schneider RK. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. Apr 1 2021;28(4):637-652 e8. doi.org/10.1016/j.stem.2020.11.004
• Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, . . . Maertens J. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine. Mar 2021;33:100787. doi.org/10.1016/j.eclinm.2021.100787
• Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, . . . von Stackelberg A. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. Mar 2 2021;325(9):843-854. doi.org/10.1001/jama.2021.0987
• Malvehy J, Samoylenko I, Schadendorf D, Gutzmer R, Grob JJ, Sacco JJ, Gorski KS, Anderson A, Pickett CA, . . . Gogas H. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. J Immunother Cancer. Mar 2021;9(3) doi.org/10.1136/jitc-2020-001621
• Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, . . . Bleckmann A. WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. J Exp Clin Cancer Res. Dec 15 2021;40(1):395. doi.org/10.1186/s13046-021-02187-z
• Morgan MA, Lange L, Schambach A. Targeted cytokine delivery: cell therapy to remodel the pre-metastatic niche. Signal Transduct Target Ther. Jul 25 2021;6(1):282. doi.org/10.1038/s41392-021-00694-1
• Moritz RKC, Gutzmer R, Zimmer L, Meier F, Ahmed MS, Sell S, Schlaak M, Kapp F, Sachse MM, . . . Weichenthal M. SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry. Eur J Cancer. Feb 2021;144:382-385. doi.org/10.1016/j.ejca.2020.11.015
• Moser O, Zimmermann M, Meyer U, Klapper W, Oschlies I, Schrappe M, Attarbaschi A, Mann G, Niggli F, . . . Woessmann W. Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica. May 1 2021;106(5):1390-1400. doi.org/10.3324/haematol.2019.244780
• Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grunwald V, Hutson TE, Kopyltsov E, . . . Investigators CT. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. Apr 8 2021;384(14):1289-1300. doi.org/10.1056/NEJMoa2035716
• Mucci A, Antonarelli G, Caserta C, Vittoria FM, Desantis G, Pagani R, Greco B, Casucci M, Escobar G, . . . Gentner B. Myeloid cell-based delivery of IFN-gamma reprograms the leukemia microenvironment and induces anti-tumoral immune responses. EMBO Mol Med. Oct 7 2021;13(10):e13598. doi.org/10.15252/emmm.202013598
• Muller D, Mazzeo P, Koch R, Bosherz MS, Welter S, von Hammerstein-Equord A, Hinterthaner M, Cordes L, Belharazem D, . . . Kuffer S. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas. BMC Med. Nov 16 2021;19(1):300. doi.org/10.1186/s12916-021-02158-3
• Najafova Z, Liu P, Wegwitz F, Ahmad M, Tamon L, Kosinsky RL, Xie W, Johnsen SA, Tuckermann J. RNF40 exerts stage-dependent functions in differentiating osteoblasts and is essential for bone cell crosstalk. Cell Death Differ. Feb 2021;28(2):700-714. doi.org/10.1038/s41418-020-00614-w
• Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, . . . Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. Jul 1 2021;113(7):808-819. doi.org/10.1093/jnci/djaa201
• Ostroumov D, Duong S, Wingerath J, Woller N, Manns MP, Timrott K, Kleine M, Ramackers W, Roessler S, . . . Wirth TC. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. Hepatology. Apr 2021;73(4):1399-1418. doi.org/10.1002/hep.31466
• Panagiota V, Meggendorfer M, Kubasch AS, Gabdoulline R, Kronke J, Mies A, Shahswar R, Kandziora C, Klement P, . . . Heuser M. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol. Jun 1 2021;96(6):E207-E210. doi.org/10.1002/ajh.26162
• Papadopoulos D, Solvie D, Baluapuri A, Endres T, Ha SA, Herold S, Kalb J, Giansanti C, Schulein-Volk C, . . . Eilers M. MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Mol Cell. Jan 6 2022;82(1):159-176 e12. doi.org/10.1016/j.molcel.2021.11.002
• Papantonis A. HMGs as rheostats of chromosomal structure and cell proliferation. Trends Genet. Nov 2021;37(11):986-994. doi.org/10.1016/j.tig.2021.07.004
• Patkar S, Heselmeyer-Haddad K, Auslander N, Hirsch D, Camps J, Bronder D, Brown M, Chen WD, Lokanga R, . . . Ried T. Hard wiring of normal tissue-specific chromosome-wide gene expression levels is an additional factor driving cancer type-specific aneuploidies. Genome Med. May 25 2021;13(1):93. doi.org/10.1186/s13073-021-00905-y
• Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, . . . Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. Apr 2021;592(7854):450-456. doi.org/10.1038/s41586-021-03362-0
• Pietzsch S, Wohlan K, Thackeray JT, Heimerl M, Schuchardt S, Scherr M, Ricke-Hoch M, Hilfiker-Kleiner D. Anthracycline-free tumor elimination in mice leads to functional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects. Basic Res Cardiol. Oct 20 2021;116(1):61. doi.org/10.1007/s00395-021-00902-7
• Poiani M, Labopin M, Battipaglia G, Beelen DW, Tischer J, Finke J, Brecht A, Forcade E, Ganser A, . . . Mohty M. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. Jan 2021;96(1):40-50. doi.org/10.1002/ajh.26000
• Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, . . . investigators SOE-O. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. May 2021;22(5):620-631. doi.org/10.1016/S1470-2045(21)00073-5
• Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, Servitjie O, Berti E, Guenova E, . . . Scarisbrick JJ. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. Apr 2021;184(4):722-730. doi.org/10.1111/bjd.19252
• Rekowski J, Huttmann A, Schmitz C, Muller SP, Kurch L, Kotzerke J, Franzius C, Weckesser M, Bengel FM, . . . Duhrsen U. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the DeltaSUV(max) Method. J Nucl Med. Jan 2021;62(1):37-42. doi.org/10.2967/jnumed.120.244145
• Roeschert I, Poon E, Henssen AG, Garcia HD, Gatti M, Giansanti C, Jamin Y, Ade CP, Gallant P, . . . Eilers M. Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nat Cancer. Mar 2021;2(3):312-326. doi.org/10.1038/s43018-020-00171-8
• Rosswog C, Bartenhagen C, Welte A, Kahlert Y, Hemstedt N, Lorenz W, Cartolano M, Ackermann S, Perner S, . . . Fischer M. Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. Nat Genet. Dec 2021;53(12):1673-1685. doi.org/10.1038/s41588-021-00951-7
• Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Stary J, . . . Wlodarski MW. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. Dec 2021;27(12):2248. doi.org/10.1038/s41591-021-01632-y
• Schafer D, Tomiuk S, Kuster LN, Rawashdeh WA, Henze J, Tischler-Hohle G, Agorku DJ, Brauner J, Linnartz C, . . . Hardt O. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun. Mar 5 2021;12(1):1453. doi.org/10.1038/s41467-021-21774-4
• Schmalbrock LK, Dolnik A, Cocciardi S, Strang E, Theis F, Jahn N, Panina E, Blatte TJ, Herzig J, . . . Bullinger L. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. Jun 3 2021;137(22):3093-3104. doi.org/10.1182/blood.2020007626
• Schultze-Florey CR, Chukhno E, Goudeva L, Blasczyk R, Ganser A, Prinz I, Forster R, Koenecke C, Odak I. Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry. Leukemia. Oct 2021;35(10):3021-3025. doi.org/10.1038/s41375-021-01348-5
• Schwab C, Roberts K, Boer JM, Gohring G, Steinemann D, Vora A, Macartney C, Hough R, Thorn Z, . . . Harrison CJ. SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood. Apr 1 2021;137(13):1835-1838. doi.org/10.1182/blood.2020008536
• Schwarzer A, Talbot SR, Selich A, Morgan M, Schott JW, Dittrich-Breiholz O, Bastone AL, Weigel B, Ha TC, . . . Rothe M. Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning. Mol Ther. Dec 1 2021;29(12):3383-3397. doi.org/10.1016/j.ymthe.2021.06.017
• Seppala TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, . . . Moller P. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Eur J Cancer. May 2021;148:124-133. doi.org/10.1016/j.ejca.2021.02.022
• Sievers P, Henneken SC, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss DE, Benzel J, . . . Sahm F. Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathol. Nov 2021;142(5):827-839. doi.org/10.1007/s00401-021-02356-6
• Sievers P, Sill M, Blume C, Tauziede-Espariat A, Schrimpf D, Stichel D, Reuss DE, Dogan H, Hartmann C, . . . German Consortium "Aggressive M. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathol. Feb 2021;141(2):281-290. doi.org/10.1007/s00401-020-02247-2
• Sievers P, Sill M, Schrimpf D, Stichel D, Reuss DE, Sturm D, Hench J, Frank S, Krskova L, . . . Sahm F. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. Jan 30 2021;23(1):34-43. https://doi.org/10.1093/neuonc/noaa251
• Sievers P, Stichel D, Sill M, Schrimpf D, Sturm D, Selt F, Ecker J, Kazdal D, Miele E, . . . Sahm F. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathol. Dec 2021;142(6):1065-1069. doi.org/10.1007/s00401-021-02369-1
• Sliwa K, Bauersachs J, Arany Z, Spracklen TF, Hilfiker-Kleiner D. Peripartum cardiomyopathy: from genetics to management. Eur Heart J. Aug 21 2021;42(32):3094-3102. doi.org/10.1093/eurheartj/ehab458
• Sliwa K, van der Meer P, Petrie MC, Frogoudaki A, Johnson MR, Hilfiker-Kleiner D, Hamdan R, Jackson AM, Ibrahim B, . . . Bauersachs J. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. Apr 2021;23(4):527-540. doi.org/10.1002/ejhf.2133
• Sofiadis K, Josipovic N, Nikolic M, Kargapolova Y, Ubelmesser N, Varamogianni-Mamatsi V, Zirkel A, Papadionysiou I, Loughran G, . . . Papantonis A. HMGB1 coordinates SASP-related chromatin folding and RNA homeostasis on the path to senescence. Mol Syst Biol. Jun 2021;17(6):e9760. doi.org/10.15252/msb.20209760
• Stanulla M, Schaeffeler E, Moricke A, Buchmann S, Zimmermann M, Igel S, Schmiegelow K, Flotho C, Hartmann H, . . . Schwab M. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia. Sep 2021;35(9):2650-2657. doi.org/10.1038/s41375-021-01203-7
• Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, . . . Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. Dec 2021;35(12):3542-3550. doi.org/10.1038/s41375-021-01328-9
• Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, . . . Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. Jun 2021;22(6):848-857. doi.org/10.1016/S1470-2045(21)00126-1
• Suwala AK, Stichel D, Schrimpf D, Kloor M, Wefers AK, Reinhardt A, Maas SLN, Kratz CP, Schweizer L, . . . Reuss DE. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. Acta Neuropathol. Jan 2021;141(1):85-100. doi.org/10.1007/s00401-020-02243-6
• Suwala AK, Stichel D, Schrimpf D, Maas SLN, Sill M, Dohmen H, Banan R, Reinhardt A, Sievers P, . . . Sahm F. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathol. Jul 2021;142(1):179-189. doi.org/10.1007/s00401-021-02302-6
• Szydlowski M, Garbicz F, Jablonska E, Gorniak P, Komar D, Pyrzynska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, . . . Juszczynski P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. Dec 1 2021;81(23):6029-6043. doi.org/10.1158/0008-5472.CAN-21-1023
• Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik VI, Schlenk RF, Paschka P, Weber D, Fiedler W, Kuhn MWM, . . . Thol F. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica. Nov 1 2021;106(11):2986-2989. doi.org/10.3324/haematol.2021.278894
• Thelen M, Wennhold K, Lehmann J, Garcia-Marquez M, Klein S, Kochen E, Lohneis P, Lechner A, Wagener-Ryczek S, . . . Schlosser HA. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. NPJ Precis Oncol. Jun 16 2021;5(1):52. doi.org/10.1038/s41698-021-00196-x
• Thielmann CM, Chorti E, Matull J, Murali R, Zaremba A, Lodde G, Jansen P, Richter L, Kretz J, . . . Griewank KG. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. Eur J Cancer. Dec 2021;159:113-124. doi.org/10.1016/j.ejca.2021.09.035
• Treiber H, Konig A, Neesse A, Richter A, Sahlmann CO, Strauss A. Liver Enzyme Elevation After (177)Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer. J Nucl Med. Jul 1 2021;62(7):1016-1019. doi.org/10.2967/jnumed.120.258533
• Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Li X, Urbach L, Danieli-Mackay A, Kuffer S, . . . Singh SK. TNF-alpha-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer. Nov 2021;2(11):1185-1203. doi.org/10.1038/s43018-021-00258-w
• Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, . . . Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. Jun 24 2021;384(25):2394-2405. doi.org/10.1056/NEJMoa2105215
• Uhlig J, Cecchini M, Sheth A, Stein S, Lacy J, Kim HS. Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. J Natl Compr Canc Netw. Feb 2 2021;19(3):307-318. doi.org/10.6004/jnccn.2020.7619
• Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, . . . Oh DY. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncol. Oct 2021;22(10):1468-1482. doi.org/10.1016/S1470-2045(21)00409-5
• van Tilburg CM, Pfaff E, Pajtler KW, Langenberg KPS, Fiesel P, Jones BC, Balasubramanian GP, Stark S, Johann PD, . . . Witt O. The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. Nov 2021;11(11):2764-2779. doi.org/10.1158/2159-8290.CD-21-0094
• Vara-Perez M, Rossi M, Van den Haute C, Maes H, Sassano ML, Venkataramani V, Michalke B, Romano E, Rillaerts K, . . . Agostinis P. BNIP3 promotes HIF-1alpha-driven melanoma growth by curbing intracellular iron homeostasis. EMBO J. May 17 2021;40(10):e106214. doi.org/10.15252/embj.2020106214
• Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, . . . Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. Sep 2021;10(5):510-521. doi.org/10.1159/000516490
• Vogel A, Martinelli E, clinicalguidelines@esmo.org EGCEa, Committee EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. Jun 2021;32(6):801-805. doi.org/10.1016/j.annonc.2021.02.014
• Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, . . . Breder V. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. Aug 2021;6(8):649-658. doi.org/10.1016/S2468-1253(21)00110-2
• Vogel A, Rimassa L, Sun HC, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, Sanchez Alvarez J, Daigl M, Orfanos P, . . . Merle P. Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer. Jun 2021;10(3):240-248. doi.org/10.1159/000515302
• Wang X, Kutschat AP, Yamada M, Prokakis E, Bottcher P, Tanaka K, Doki Y, Hamdan FH, Johnsen SA. Bromodomain protein BRDT directs DeltaNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas. Cell Death Differ. Jul 2021;28(7):2207-2220. doi.org/10.1038/s41418-021-00751-w
• Watermann C, Pasternack H, Idel C, Ribbat-Idel J, Bragelmann J, Kuppler P, Offermann A, Jonigk D, Kuhnel MP, . . . Krupar R. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clin Cancer Res. Jan 15 2021;27(2):632-644. doi.org/10.1158/1078-0432.CCR-20-0197
• Wehkamp U, Mitteldorf C, Stendel S, Stranzenbach R, Nicolay JP, Wobser M, Weichenthal M, Schneiderbauer R, Klemke CD, . . . Assaf C. Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network. Br J Dermatol. Jul 2021;185(1):228-230. doi.org/10.1111/bjd.19823
• Weissinger EM, Metzger J, Schleuning M, Schmid C, Messinger D, Beutel G, Wagner-Drouet EM, Schetelig J, Baurmann H, . . . Ganser A. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia. Jun 2021;35(6):1763-1772. doi.org/10.1038/s41375-020-01059-3
• Wessely A, Steeb T, Berking C, Schlaak M, Heppt MV, German Dermatologic Cooperative Oncology G. Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. Eur J Cancer. Jan 2021;143:43-45. doi.org/10.1016/j.ejca.2020.10.021
• Wicklein R, Heidegger S, Verbeek M, Eiz-Vesper B, Maecker-Kolhoff B, Kirschke JS, Page A, Korn T, Hemmer B, . . . Deschauer M. Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report. Neurol Neuroimmunol Neuroinflamm. Jul 2021;8(5)https://doi.org/10.1212/NXI.0000000000001042
• Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging. Nov 2021;48(12):4077-4088. doi.org/10.1007/s00259-021-05412-1
• Winter G, Kirschner-Schwabe R, Groeneveld-Krentz S, Escherich G, Moricke A, von Stackelberg A, Stanulla M, Bailey S, Richter L, . . . Kratz CP. Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li-Fraumeni syndrome. Leukemia. May 2021;35(5):1475-1479. doi.org/10.1038/s41375-021-01163-y
• Woelber L, Prieske K, Eulenburg C, Oliveira-Ferrer L, de Gregorio N, Klapdor R, Kalder M, Braicu I, Fuerst S, . . . Burandt E. p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynakologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. Am J Obstet Gynecol. Jun 2021;224(6):595 e1-595 e11. doi.org/10.1016/j.ajog.2020.12.1220
• Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, Nirmal AJ, Liu H, Yang L, . . . Weinstock DM. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood. Mar 31 2022;139(13):2024-2037. doi.org/10.1182/blood.2021014701
• Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, . . . investigators ACTs. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. Jan 2021;35(1):143-155. doi.org/10.1038/s41375-020-0838-5
• Yamada Y, Simon-Keller K, Belharazem-Vitacolonnna D, Bohnenberger H, Kriegsmann M, Kriegsmann K, Hamilton G, Graeter T, Preissler G, . . . Marx A. A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes. J Thorac Oncol. Jun 2021;16(6):1003-1016. doi.org/10.1016/j.jtho.2021.02.008
• Zaliova M, Potuckova E, Lukes J, Winkowska L, Starkova J, Janotova I, Sramkova L, Stary J, Zuna J, . . . Trka J. Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia. Haematologica. Mar 1 2021;106(3):886-890. doi.org/10.3324/haematol.2020.249094
• Zampetidis CP, Galanos P, Angelopoulou A, Zhu Y, Polyzou A, Karamitros T, Kotsinas A, Lagopati N, Mourkioti I, . . . Gorgoulis VG. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. Mol Cell. Dec 2 2021;81(23):4907-4923 e8. doi.org/10.1016/j.molcel.2021.10.017
• Zaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, Gutzmer R, Utikal J, . . . Livingstone E. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. Eur J Cancer. Jul 2021;152:139-154. doi.org/10.1016/j.ejca.2021.04.032
• Zhang S, Ubelmesser N, Josipovic N, Forte G, Slotman JA, Chiang M, Gothe HJ, Gusmao EG, Becker C, . . . Papantonis A. RNA polymerase II is required for spatial chromatin reorganization following exit from mitosis. Sci Adv. Oct 22 2021;7(43):eabg8205. doi.org/10.1126/sciadv.abg8205
• Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. Apr 2021;230:164-196. doi.org/10.1016/j.trsl.2020.11.012
• Zoellner AK, Unterhalt M, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, . . . European Mantle Cell Lymphoma N. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. Sep 2021;8(9):e648-e657. doi.org/10.1016/S2352-3026(21)00195-2

2020

• Agrawal M, Schwarz P, Giaimo BD, Bedzhov I, Corbacioglu A, Weber D, Gaidzik VI, Jahn N, Rucker FG, . . . Oswald F. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML). Leukemia. Feb 2020;34(2):630-634. doi.org/10.1038/s41375-019-0551-4
• Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, . . . *German Dermatological Cooperative Oncology G. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. Mar 2020;8(1) doi.org/10.1136/jitc-2019-000333
• Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbe C, Svane IM, McNeil C, . . . Maio M. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. J Immunother Cancer. Jun 2020;8(1) doi.org/10.1136/jitc-2019-000391
• Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Biondi A, Cario G, Cazzaniga G, . . . on behalf of the A-BFMSG. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. Jun 2020;34(6):1694-1700. doi.org/10.1038/s41375-019-0670-y
• Banan R, Stichel D, Bleck A, Hong B, Lehmann U, Suwala A, Reinhardt A, Schrimpf D, Buslei R, . . . Reuss DE. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol. Oct 2020;140(4):569-581. doi.org/10.1007/s00401-020-02194-y
• Bartels S, Faisal M, Busche G, Schlue J, Hasemeier B, Schipper E, Vogtmann J, Westphal L, Lehmann U, . . . Kreipe H. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. May 2020;34(5):1364-1372. doi.org/10.1038/s41375-019-0668-5
• Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Remenyi P, Wagner-Drouet EM, Hauptrock B, Dreger P, . . . Markiewicz M. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. Jan 2020;7(1):e28-e39. doi.org/10.1016/S2352-3026(19)30157-7
• Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, . . . Papaemmanuil E. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. Oct 2020;26(10):1549-1556. doi.org/10.1038/s41591-020-1008-z
• Berthold F, Faldum A, Ernst A, Boos J, Dilloo D, Eggert A, Fischer M, Fruhwald M, Henze G, . . . Simon T. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann Oncol. Mar 2020;31(3):422-429. doi.org/10.1016/j.annonc.2019.11.011
• Best J, Bechmann LP, Sowa JP, Sydor S, Dechene A, Pflanz K, Bedreli S, Schotten C, Geier A, . . . Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. Mar 2020;18(3):728-735 e4. doi.org/10.1016/j.cgh.2019.11.012
• Blaeschke F, Willier S, Stenger D, Lepenies M, Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, . . . Feuchtinger T. Leukemia-induced dysfunctional TIM-3(+)CD4(+) bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. Leukemia. Oct 2020;34(10):2607-2620. doi.org/10.1038/s41375-020-0793-1
• Borde J, Ernst C, Wappenschmidt B, Niederacher D, Weber-Lassalle K, Schmidt G, Hauke J, Quante AS, Weber-Lassalle N, . . . Hahnen E. Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. J Natl Cancer Inst. Jul 1 2021;113(7):893-899. doi.org/10.1093/jnci/djaa203
• Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MS, Westphal M, Pietsch T, von Deimling A, . . . Weber RG. FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathol. Jan 2020;139(1):175-192. doi.org/10.1007/s00401-019-02067-z
• Cader FZ, Hu X, Goh WL, Wienand K, Ouyang J, Mandato E, Redd R, Lawton LN, Chen PH, . . . Shipp MA. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. Sep 2020;26(9):1468-1479. doi.org/10.1038/s41591-020-1006-1
• Castel D, Kergrohen T, Tauziede-Espariat A, Mackay A, Ghermaoui S, Lechapt E, Pfister SM, Kramm CM, Boddaert N, . . . Debily MA. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathol. Jun 2020;139(6):1109-1113. doi.org/10.1007/s00401-020-02142-w
• Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, . . . Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. Sep 2020;22(9):1504-1524. doi.org/10.1002/ejhf.1957
• Chaturvedi A, Goparaju R, Gupta C, Weder J, Klunemann T, Araujo Cruz MM, Kloos A, Goerlich K, Schottmann R, . . . Heuser M. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia. Feb 2020;34(2):416-426. doi.org/10.1038/s41375-019-0582-x
• Chen CCL, Deshmukh S, Jessa S, Hadjadj D, Lisi V, Andrade AF, Faury D, Jawhar W, Dali R, . . . Jabado N. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. Dec 10 2020;183(6):1617-1633 e22. doi.org/10.1016/j.cell.2020.11.012
• Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, . . . Lo-Coco F. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. Mar 2020;34(3):914-918. doi.org/10.1038/s41375-019-0589-3
• Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, Pop-Damkov P, Su N, Roamio Franklin VN, . . . Drew L. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. Feb 15 2020;26(4):922-934. doi.org/10.1158/1078-0432.CCR-19-1853
• Clarke M, Mackay A, Ismer B, Pickles JC, Tatevossian RG, Newman S, Bale TA, Stoler I, Izquierdo E, . . . Jones C. Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discov. Jul 2020;10(7):942-963. doi.org/10.1158/2159-8290.CD-19-1030
• Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, . . . Heuser M. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. Jul 14 2020;13(1):92. doi.org/10.1186/s13045-020-00929-8
• Crisa E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, . . . Mufti GJ. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia. Sep 2020;34(9):2441-2450. doi.org/10.1038/s41375-020-0728-x
• Dai Z, Song G, Balakrishnan A, Yang T, Yuan Q, Mobus S, Weiss AC, Bentler M, Zhu J, . . . Sharma AD. Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells. Gut. Jun 2020;69(6):1104-1115. doi.org/10.1136/gutjnl-2019-318812
• de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, Bauersachs J, Bertero E, Coats AJS, . . . Backs J. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. Dec 2020;22(12):2272-2289. doi.org/10.1002/ejhf.2029
• Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns JM, Ross TL, Bengel FM. Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. J Nucl Med. Nov 2020;61(11):1602-1606. doi.org/10.2967/jnumed.120.241588
• Desch AK, Hartung K, Botzen A, Brobeil A, Rummel M, Kurch L, Georgi T, Jox T, Bielack S, . . . Brauninger A. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. Leukemia. Jan 2020;34(1):151-166. doi.org/10.1038/s41375-019-0541-6
• Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, . . . trial i. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. Feb 2020;21(2):271-282. doi.org/10.1016/S1470-2045(19)30691-6
• Dohner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, . . . Bloomfield CD. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. Jan 30 2020;135(5):371-380. doi.org/10.1182/blood.2019002697
• Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Kloss S, Kloth C, Mangare C, Bonifacius A, . . . Eiz-Vesper B. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J Immunother Cancer. Oct 2020;8(2)https://doi.org/10.1136/jitc-2020-000736
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, . . . Robert C. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. J Clin Oncol. Nov 20 2020;38(33):3925-3936. doi.org/10.1200/JCO.20.02110
• Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, . . . Suciu S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. Apr 1 2020;6(4):519-527. doi.org/10.1001/jamaoncol.2019.5570
• Erarslan-Uysal B, Kunz JB, Rausch T, Richter-Pechanska P, van Belzen IA, Frismantas V, Bornhauser B, Ordonez-Rueada D, Paulsen M, . . . Kulozik AE. Chromatin accessibility landscape of pediatric T-lymphoblastic leukemia and human T-cell precursors. EMBO Mol Med. Sep 7 2020;12(9):e12104. doi.org/10.15252/emmm.202012104
• Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, . . . Schmidt MK. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nat Commun. Jan 16 2020;11(1):312. doi.org/10.1038/s41467-019-14100-6
• Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, . . . Dunning AM. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. Jan 2020;52(1):56-73. doi.org/10.1038/s41588-019-0537-1
• Fish K, Comoglio F, Shaffer AL, 3rd, Ji Y, Pan KT, Scheich S, Oellerich A, Doebele C, Ikeda M, . . . Oellerich T. Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. Proc Natl Acad Sci U S A. Oct 20 2020;117(42):26318-26327. doi.org/10.1073/pnas.2007946117
• Furstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, . . . Eichhorst B. COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. Aug 2020;34(8):2225-2229. doi.org/10.1038/s41375-020-0941-7
• Gandhi MK, Hoang T, Law SC, Brosda S, O'Rourke K, Tobin JWD, Vari F, Murigneux V, Fink L, . . . Keane C. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood. Mar 18 2021;137(11):1468-1477. doi.org/10.1182/blood.2020008520
• Giardino S, de Latour RP, Aljurf M, Eikema DJ, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhauser M, . . . Marrow Transplantation g. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. Am J Hematol. Jul 2020;95(7):809-816. doi.org/10.1002/ajh.25810
• Giesel FL, Adeberg S, Syed M, Lindner T, Jimenez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, . . . Kratochwil C. FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. Feb 2021;62(2):201-207. doi.org/10.2967/jnumed.120.245084
• Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, . . . Karlsen TH. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology. Oct 2020;72(4):1253-1266. doi.org/10.1002/hep.31110
• Goveia J, Rohlenova K, Taverna F, Treps L, Conradi LC, Pircher A, Geldhof V, de Rooij L, Kalucka J, . . . Carmeliet P. An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. Cancer Cell. Jan 13 2020;37(1):21-36 e13. doi.org/10.1016/j.ccell.2019.12.001
• Grunwald V, Karch A, Schuler M, Schoffski P, Kopp HG, Bauer S, Kasper B, Lindner LH, Chemnitz JM, . . . Kunitz A. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. J Clin Oncol. Oct 20 2020;38(30):3555-3564. doi.org/10.1200/JCO.20.00714
• Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, . . . Meier F. Melanoma brain metastases - Interdisciplinary management recommendations 2020. Cancer Treat Rev. Sep 2020;89:102083. doi.org/10.1016/j.ctrv.2020.102083
• Haenssle HA, Fink C, Toberer F, Winkler J, Stolz W, Deinlein T, Hofmann-Wellenhof R, Lallas A, Emmert S, . . . Level IIG. Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison with 96 dermatologists working under less artificial conditions. Ann Oncol. Jan 2020;31(1):137-143. doi.org/10.1016/j.annonc.2019.10.013
• Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, . . . Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology. Jul 2020;72(1):198-212. doi.org/10.1002/hep.31022
• He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, . . . Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. Jul 16 2020;13(1):95. doi.org/10.1186/s13045-020-00928-9
• Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, . . . the German CMLSG. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. Aug 2020;34(8):2074-2086. doi.org/10.1038/s41375-020-0826-9
• Herbrueggen H, Mueller S, Rohde J, Arias Padilla L, Moericke A, Attarbaschi A, Zimmermann M, Ratei R, Brueggemann M, . . . Burkhardt B. Treatment and outcome of IG-MYC(+) neoplasms with precursor B-cell phenotype in childhood and adolescence. Leukemia. Mar 2020;34(3):942-946. doi.org/10.1038/s41375-019-0606-6
• Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiol Rev. Oct 1 2020;100(4):1707-1751. doi.org/10.1152/physrev.00042.2019
• Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman LR, Wang ES, Fiedler W, Baldus C, . . . Kramer A. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia. Nov 2020;34(11):2903-2913. doi.org/10.1038/s41375-020-0996-5
• Hinze L, Labrosse R, Degar J, Han T, Schatoff EM, Schreek S, Karim S, McGuckin C, Sacher JR, . . . Gutierrez A. Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discov. Nov 2020;10(11):1690-1705. doi.org/10.1158/2159-8290.CD-19-1472
• Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, Gorlov I, Xiao X, Han Y, . . . Amos CI. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. May 11 2020;11(1):2220. doi.org/10.1038/s41467-020-15905-6
• Jia J, Absmeier E, Holton N, Pietrzyk-Brzezinska AJ, Hackert P, Bohnsack KE, Bohnsack MT, Wahl MC. The interaction of DNA repair factors ASCC2 and ASCC3 is affected by somatic cancer mutations. Nat Commun. Nov 2 2020;11(1):5535. doi.org/10.1038/s41467-020-19221-x
• Kachuri L, Johansson M, Rashkin SR, Graff RE, Bosse Y, Manem V, Caporaso NE, Landi MT, Christiani DC, . . . Hung RJ. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. Nat Commun. Jan 7 2020;11(1):27. doi.org/10.1038/s41467-019-13855-2
• Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Kronke J, Theis F, Rucker FG, Teleanu MV, . . . Dohner K. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. Dec 24 2020;136(26):3041-3050. doi.org/10.1182/blood.2020005998
• Kloos A, Mintzas K, Winckler L, Gabdoulline R, Alwie Y, Jyotsana N, Kattre N, Schottmann R, Scherr M, . . . Heuser M. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia. Nov 2020;34(11):2951-2963. doi.org/10.1038/s41375-020-0929-3
• Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, Pfohler C, Gesierich A, . . . Ugurel S. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. J Immunother Cancer. May 2020;8(1)https://doi.org/10.1136/jitc-2019-000395
• Knorr F, Brugieres L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, Burke GAA, Uyttebroeck A, . . . European Inter-Group for Childhood Non-Hodgkin L. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. Dec 1 2020;38(34):3999-4009. doi.org/10.1200/JCO.20.00157
• Koch C, Kuske A, Joosse SA, Yigit G, Sflomos G, Thaler S, Smit DJ, Werner S, Borgmann K, . . . Pantel K. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med. Sep 7 2020;12(9):e11908. doi.org/10.15252/emmm.201911908
• Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F, Begus-Nahrmann Y, Johnsen SA. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. Apr 2020;27(4):1328-1340. doi.org/10.1038/s41418-019-0420-8
• Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, . . . Schmidt MK. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. Am J Hum Genet. Nov 5 2020;107(5):837-848. doi.org/10.1016/j.ajhg.2020.09.001
• Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, . . . Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. Mar 2021;35(3):835-849. doi.org/10.1038/s41375-020-0917-7
• Leiter U, Loquai C, Reinhardt L, Rafei-Shamsabadi D, Gutzmer R, Kaehler K, Heinzerling L, Hassel JC, Glutsch V, . . . Ugurel S. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer. Oct 2020;8(2) doi.org/10.1136/jitc-2020-000897
• Logotheti S, Marquardt S, Gupta SK, Richter C, Edelhauser BAH, Engelmann D, Brenmoehl J, Sohnchen C, Murr N, . . . Putzer BM. LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1. Theranostics. Jul 29 2020;10(21):9620-9643. doi.org/10.7150/thno.44176
• Lubbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, . . . Team DS. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial. J Clin Oncol. Jan 20 2020;38(3):257-270. doi.org/10.1200/JCO.19.01053
• Lukas M, Velten B, Sellner L, Tomska K, Huellein J, Walther T, Wagner L, Muley C, Wu B, . . . Zenz T. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies. Leukemia. Nov 2020;34(11):2934-2950. doi.org/10.1038/s41375-020-0846-5
• Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, . . . Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. Nov 2020;22(11):1945-1960. doi.org/10.1002/ejhf.1920
• Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, . . . Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. Jul 9 2020;136(2):157-170. doi.org/10.1182/blood.2020004850
• Malyszko J, Bamias A, Danesh FR, Debska-Slizien A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, . . . Conference P. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney Int. Dec 2020;98(6):1407-1418. doi.org/10.1016/j.kint.2020.07.012
• Mezzatesta C, Abduli L, Guinot A, Eckert C, Schewe D, Zaliova M, Vinti L, Marovca B, Tsai YC, . . . Bornhauser BC. Repurposing anthelmintic agents to eradicate resistant leukemia. Blood Cancer J. Jun 26 2020;10(6):72. doi.org/10.1038/s41408-020-0339-9
• Moehler M, Maderer A, Thuss-Patience PC, Brenner B, Meiler J, Ettrich TJ, Hofheinz RD, Al-Batran SE, Vogel A, . . . Lorenzen S. Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol. Feb 2020;31(2):228-235. doi.org/10.1016/j.annonc.2019.10.018
• Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, . . . Rutkowski S. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. J Clin Oncol. Jun 20 2020;38(18):2028-2040. doi.org/10.1200/JCO.19.03057
• Patil S, Steuber B, Kopp W, Kari V, Urbach L, Wang X, Kuffer S, Bohnenberger H, Spyropoulou D, . . . Hessmann E. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Res. Nov 1 2020;80(21):4620-4632. doi.org/10.1158/0008-5472.CAN-20-0672
• Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, . . . Investigators A-OE-o. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. May 2020;21(5):699-709. doi.org/10.1016/S1470-2045(20)30142-X
• Poire X, Labopin M, Polge E, Volin L, Finke J, Ganser A, Blaise D, Yakoub-Agha I, Beelen D, . . . Nagler A. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. Am J Hematol. Mar 2020;95(3):282-294. doi.org/10.1002/ajh.25714
• Porta C, Bamias A, Danesh FR, Debska-Slizien A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, . . . Conference P. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. Nov 2020;98(5):1108-1119. doi.org/10.1016/j.kint.2020.06.046
• Potsch MS, Ishida J, Palus S, Tschirner A, von Haehling S, Doehner W, Anker SD, Springer J. MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. J Cachexia Sarcopenia Muscle. Apr 2020;11(2):594-605. doi.org/10.1002/jcsm.12537
• Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, . . . Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. Nov 2020;22(11):1966-1983. doi.org/10.1002/ejhf.2017
• Reinke S, Brockelmann PJ, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, Kotrova M, Pal K, Bruggemann M, . . . Klapper W. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. Dec 17 2020;136(25):2851-2863. doi.org/10.1182/blood.2020008553
• Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, . . . Dokal I. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun. Feb 25 2020;11(1):1044. doi.org/10.1038/s41467-020-14829-5
• Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, . . . Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. Jun 2020;8(1) doi.org/10.1136/jitc-2020-000775
• Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Herbst SA, . . . Dietrich S. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol. Jul 2020;22(7):896-906. doi.org/10.1038/s41556-020-0532-x
• Sauer MG, Lang PJ, Albert MH, Bader P, Creutzig U, Eyrich M, Greil J, Gruhn B, Holter W, . . . Borkhardt A. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. Feb 2020;34(2):613-624. doi.org/10.1038/s41375-019-0584-8
• Schleich K, Kase J, Dorr JR, Trescher S, Bhattacharya A, Yu Y, Wailes EM, Fan DNY, Lohneis P, . . . Schmitt CA. H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients. Nat Commun. Jul 20 2020;11(1):3651. doi.org/10.1038/s41467-020-17467-z
• Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, . . . Dohner H. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J Clin Oncol. Feb 20 2020;38(6):623-632. doi.org/10.1200/JCO.19.01406
• Schmaelter AK, Labopin M, Socie G, Itala-Remes M, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Ganser A, . . . Mohty M. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. Mar 3 2020;10(3):26. doi.org/10.1038/s41408-020-0296-3
• Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, . . . Tournilhac O. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. May 13 2021;137(19):2646-2656. doi.org/10.1182/blood.2020008825
• Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, . . . Geissler EK. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Ann Surg. Nov 2020;272(5):855-862. doi.org/10.1097/SLA.0000000000004280
• Schweizer L, Thierfelder F, Thomas C, Soschinski P, Suwala A, Stichel D, Wefers AK, Wessels L, Misch M, . . . Koch A. Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. Acta Neuropathol. Dec 2020;140(6):893-906. doi.org/10.1007/s00401-020-02218-7
• Sebestyen Z, Prinz I, Dechanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. Mar 2020;19(3):169-184. doi.org/10.1038/s41573-019-0038-z
• Sill H, Zebisch A, Haase D. Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder. Clin Cancer Res. Oct 15 2020;26(20):5304-5309. doi.org/10.1158/1078-0432.CCR-20-2272
• Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Huttl KS, Glehr G, Klapper W, . . . German High Grade Non-Hodgkin's Lymphoma Study G. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. Feb 2020;34(2):543-552. doi.org/10.1038/s41375-019-0573-y
• Stanulla M, Cave H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. Jan 23 2020;135(4):252-260. doi.org/10.1182/blood.2019000813
• Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, . . . Investigators P. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. Jun 4 2020;382(23):2197-2206. doi.org/10.1056/NEJMoa2003892
• Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, Weiss KH, Gotthardt D, . . . Morgan MY. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology. Jul 2020;72(1):88-102. doi.org/10.1002/hep.30996
• Tocchetti CG, Ameri P, de Boer RA, D'Alessandra Y, Russo M, Sorriento D, Ciccarelli M, Kiss B, Bertrand L, . . . Thum T. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. Sep 1 2020;116(11):1820-1834. doi.org/10.1093/cvr/cvaa222
• Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, . . . Winkler F. Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Res. Oct 15 2020;80(20):4314-4323. doi.org/10.1158/0008-5472.CAN-20-0291
• Vogel A, Saborowski A. Adjuvant (131)I-metuximab in hepatocellular carcinoma: a new option for an old drug? Lancet Gastroenterol Hepatol. Jun 2020;5(6):517-519. doi.org/10.1016/S2468-1253(20)30004-2
• Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev. Jan 2020;82:101946. doi.org/10.1016/j.ctrv.2019.101946
• Wagner FR, Dienemann C, Wang H, Stutzer A, Tegunov D, Urlaub H, Cramer P. Structure of SWI/SNF chromatin remodeller RSC bound to a nucleosome. Nature. Mar 2020;579(7799):448-451. doi.org/10.1038/s41586-020-2088-0
• Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, . . . Xin HW. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. Aug 3 2020;13(1):107. doi.org/10.1186/s13045-020-00939-6
• Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, . . . Strauss HW. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. J Nucl Med. Dec 2020;61(Suppl 2):263S-272S. doi.org/10.2967/jnumed.120.254532
• Wei AH, Dohner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, . . . Investigators QA-T. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. Dec 24 2020;383(26):2526-2537. doi.org/10.1056/NEJMoa2004444
• Weiterer SS, Meier-Soelch J, Georgomanolis T, Mizi A, Beyerlein A, Weiser H, Brant L, Mayr-Buro C, Jurida L, . . . Kracht M. Distinct IL-1alpha-responsive enhancers promote acute and coordinated changes in chromatin topology in a hierarchical manner. EMBO J. Jan 2 2020;39(1):e101533. doi.org/10.15252/embj.2019101533
• Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, . . . Rowe SP. (18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. Jan 1 2020;10(1):1-16. doi.org/10.7150/thno.37894
• Wirth TC, Niemann J, Kuhnel F. Live vaccines-a short-cut to cancer viro-immunotherapy. EMBO Mol Med. Jan 9 2020;12(1):e11496. doi.org/10.15252/emmm.201911496
• Woessmann W, Zimmermann M, Meinhardt A, Muller S, Hauch H, Knorr F, Oschlies I, Klapper W, Niggli F, . . . Burkhardt B. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy. Blood. Apr 2 2020;135(14):1124-1132. doi.org/10.1182/blood.2019003591
• Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, . . . Investigators Gm-. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. Sep 3 2020;383(10):944-957. doi.org/10.1056/NEJMoa2002787
• Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, . . . Tischkowitz M. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. Mar 1 2020;38(7):674-685. doi.org/10.1200/JCO.19.01907
• Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horvath J, Kast K, Niederacher D, . . . Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst. Dec 14 2020;112(12):1242-1250. doi.org/10.1093/jnci/djaa030
• Yang Y, Wu L, Shu XO, Cai Q, Shu X, Li B, Guo X, Ye F, Michailidou K, . . . Long J. Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent. J Natl Cancer Inst. Mar 1 2020;112(3):295-304. doi.org/10.1093/jnci/djz109
• Yen CJ, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, . . . Kang YK. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer. Aug 2020;9(4):440-454. doi.org/10.1159/000506946
• Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, . . . Garcia-Closas M. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. Jun 2020;52(6):572-581. https://doi.org/10.1038/s41588-020-0609-2 
• Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, . . . Dermatologic Cooperative Oncology G. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. May 16 2020;395(10236):1558-1568. doi.org/10.1016/S0140-6736(20)30417-7

2019

• Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, . . . Shipp MA. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. Dec 26 2019;134(26):2369-2382. doi.org/10.1182/blood.2019002067
• Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, . . . Immunobiology Working Party - Solid Tumor S-c. Development of adaptive immune effector therapies in solid tumors. Ann Oncol. Nov 1 2019;30(11):1740-1750. doi.org/10.1093/annonc/mdz285
• Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, . . . German Rectal Cancer Study G. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol. Dec 1 2019;37(34):3212-3222. doi.org/10.1200/JCO.19.00308
• Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, . . . Pajtler KW. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol. Dec 2019;138(6):1075-1089. doi.org/10.1007/s00401-019-02056-2
• Heppt MV, Amaral T, Kahler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, . . . Berking C. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. Nov 13 2019;7(1):299. doi.org/10.1186/s40425-019-0800-0
• Huang Y, Mouttet B, Warnatz HJ, Risch T, Rietmann F, Frommelt F, Ngo QA, Dobay MP, Marovca B, . . . Bourquin JP. The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer Cell. Dec 9 2019;36(6):630-644 e9. doi.org/10.1016/j.ccell.2019.10.004
• Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, . . . Schadendorf D. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. Dec 2019;25(12):1916-1927. doi.org/10.1038/s41591-019-0654-5
• Maluski M, Ghosh A, Herbst J, Scholl V, Baumann R, Huehn J, Geffers R, Meyer J, Maul H, . . . Sauer MG. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. J Clin Invest. Dec 2 2019;129(12):5108-5122. doi.org/10.1172/JCI126350
• Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, . . . Hassel JC. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. J Clin Oncol. Nov 20 2019;37(33):3142-3151. doi.org/10.1200/JCO.19.00489
• Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, . . . Investigators P-. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. Dec 19 2019;381(25):2416-2428. doi.org/10.1056/NEJMoa1911361
• Rucker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, . . . Dohner K. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood. Nov 7 2019;134(19):1608-1618. doi.org/10.1182/blood.2019001425
• Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, Davidsson OB, Day FR, Sulem P, . . . Perry JRB. Genetic predisposition to mosaic Y chromosome loss in blood. Nature. Nov 2019;575(7784):652-657. doi.org/10.1038/s41586-019-1765-3
• Vijayakrishnan J, Qian M, Studd JB, Yang W, Kinnersley B, Law PJ, Broderick P, Raetz EA, Allan J, . . . Yang JJ. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nat Commun. Nov 25 2019;10(1):5348. doi.org/10.1038/s41467-019-13069-6
• Wildung M, Esser TU, Grausam KB, Wiedwald C, Volceanov-Hahn L, Riedel D, Beuermann S, Li L, Zylla J, . . . Lize M. Transcription factor TAp73 and microRNA-449 complement each other to support multiciliogenesis. Cell Death Differ. Dec 2019;26(12):2740-2757. doi.org/10.1038/s41418-019-0332-7

© Photo from MART PRODUCTION